Difference between revisions of "Anaplastic glioma"
m (→References) |
m |
||
Line 1: | Line 1: | ||
'''Use of this site is subject to you reading and agreeing with the terms set forth in the [[HemOnc.org_-_A_Hematology_Oncology_Wiki:General_disclaimer|disclaimer]].''' | '''Use of this site is subject to you reading and agreeing with the terms set forth in the [[HemOnc.org_-_A_Hematology_Oncology_Wiki:General_disclaimer|disclaimer]].''' | ||
− | Is there a regimen missing from this list? | + | Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are [[How_to_contribute|invited to contribute to the site]]. |
{| class="wikitable" style="float:right; margin-right: 5px;" | {| class="wikitable" style="float:right; margin-right: 5px;" | ||
|- | |- | ||
− | |<div style="background-color: #66FF66; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] | + | |<div style="background-color: #66FF66; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} regimens on this page</b></font></div> |
− | <div style="background-color: #66CCFF; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] | + | <div style="background-color: #66CCFF; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} variants on this page</b></font></div> |
|} | |} | ||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
Line 34: | Line 34: | ||
|- | |- | ||
|} | |} | ||
− | + | ====Chemotherapy==== | |
− | *[[Procarbazine (Matulane)]] 60 mg/ | + | *[[Procarbazine (Matulane)]] 60 mg/m<sup>2</sup> PO once per day on days 8 to 21 |
− | *[[Lomustine (Ceenu)]] 110 mg/ | + | *[[Lomustine (Ceenu)]] 110 mg/m<sup>2</sup> PO once on day 1 |
*[[Vincristine (Oncovin)]] 2 mg IV once per day on days 8 & 29 | *[[Vincristine (Oncovin)]] 2 mg IV once per day on days 8 & 29 | ||
− | '''8-week cycle | + | '''8-week cycle for 4 cycles''' |
''Patients with stable disease or better received '''2 more cycles of PCV'''. At time of disease progression patients proceeded to receive [[#Radiation_therapy_2|radiation therapy]].'' | ''Patients with stable disease or better received '''2 more cycles of PCV'''. At time of disease progression patients proceeded to receive [[#Radiation_therapy_2|radiation therapy]].'' | ||
Line 88: | Line 88: | ||
''Adjuvant radiation alone; used as a comparator arm in the referenced trials.'' | ''Adjuvant radiation alone; used as a comparator arm in the referenced trials.'' | ||
− | + | ====Radiotherapy==== | |
*Radiation therapy with 1.8 to 2 Gy fractions given over 6 weeks for a total dose of 60 Gy | *Radiation therapy with 1.8 to 2 Gy fractions given over 6 weeks for a total dose of 60 Gy | ||
Line 104: | Line 104: | ||
|[[#toc|back to top]] | |[[#toc|back to top]] | ||
|} | |} | ||
− | + | ===Regimen {{#subobject:31c739|Variant=1}}=== | |
+ | {| border="1" style="text-align:center;" !align="left" | ||
+ | |'''Study''' | ||
+ | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
+ | |'''Comparator''' | ||
+ | |- | ||
+ | |[http://thejns.org/doi/abs/10.3171/jns.1989.71.1.0001 Shapiro et al. 1989 (BTCG 8001)] | ||
+ | |<span | ||
+ | style="background:#00CD00; | ||
+ | padding:3px 6px 3px 6px; | ||
+ | border-color:black; | ||
+ | border-width:2px; | ||
+ | border-style:solid;">Phase III</span> | ||
+ | |Carmustine/Procarbazine & RT<br> Carmustine & Hydrea/Procarbazine & VM-26 & RT | ||
+ | |- | ||
+ | |} | ||
+ | |||
+ | ====Radiotherapy==== | ||
+ | *Radiation therapy starting within 3 weeks after surgical resection, with one of the following: | ||
+ | **Whole brain: 172 cGy (rads) fractions x 35 fractions, given over 7 weeks for a total dose of 6020 cGy (6020 rads/~1700 rets) | ||
+ | **Whole brain & cone down: 172 cGy (rads) fractions x 25 fractions, given over 5 weeks for a total dose of 4300 cGy (4300 rads), then coned-down boost of 172 cGy (rads) fractions x 10 fractions, given over 2 weeks for a dose of 1720 cGy (rads), and a total cumulative dose of 6020 cGy (rads) | ||
+ | |||
+ | ''One course, followed by:'' | ||
+ | ====Chemotherapy==== | ||
+ | *[[Carmustine (BiCNU)]] 80 mg/m<sup>2</sup> IV over 30 to 60 minutes once per day on days 1 to 3 | ||
+ | |||
+ | '''8-week cycles, with no more than a maximum total dose of 1500 mg/m<sup>2</sup> [[Carmustine (BiCNU)]] given''' | ||
+ | |||
+ | Supportive care: | ||
+ | *Pulmonary function tests (PFTs) checked before start of therapy, and then when cumulative dose of [[Carmustine (BiCNU)]] reaches 800 mg/m<sup>2</sup> and 1200 mg/m<sup>2</sup> | ||
+ | |||
+ | ===References=== | ||
+ | # Shapiro WR, Green SB, Burger PC, Mahaley MS Jr, Selker RG, VanGilder JC, Robertson JT, Ransohoff J, Mealey J Jr, Strike TA et al. Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001. J Neurosurg. 1989 Jul;71(1):1-9. [http://thejns.org/doi/abs/10.3171/jns.1989.71.1.0001 link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/2661738 PubMed] | ||
==RT -> PCV {{#subobject:1097a5|Regimen=1}}== | ==RT -> PCV {{#subobject:1097a5|Regimen=1}}== | ||
Line 130: | Line 162: | ||
|} | |} | ||
− | ''Radiation therapy starts preferably within 3, but no more than 6, weeks after neurosurgery:' | + | ''Radiation therapy starts preferably within 3, but no more than 6, weeks after neurosurgery:'' |
− | * | + | ====Radiotherapy==== |
+ | *Either: | ||
**2.25 Gy fractions x 20 fractions, given 5 days per week over 4 weeks, total dose of 45 Gy | **2.25 Gy fractions x 20 fractions, given 5 days per week over 4 weeks, total dose of 45 Gy | ||
**or 2 Gy fractions x 30 fractions, given 5 days per week over 6 weeks, total dose of 60 Gy | **or 2 Gy fractions x 30 fractions, given 5 days per week over 6 weeks, total dose of 60 Gy | ||
Line 137: | Line 170: | ||
''Chemotherapy begins 3 to 4 weeks after completion of radiation therapy:'' | ''Chemotherapy begins 3 to 4 weeks after completion of radiation therapy:'' | ||
− | *[[Procarbazine (Matulane)]] 100 mg/ | + | ====Chemotherapy==== |
− | *[[Lomustine (Ceenu)]] 100 mg/ | + | *[[Procarbazine (Matulane)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 10 |
− | *[[Vincristine (Oncovin)]] 1.5 mg/ | + | *[[Lomustine (Ceenu)]] 100 mg/m<sup>2</sup> PO once on day 1 |
+ | *[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> (maximum dose of 2 mg) IV fast infusion once on day 1 | ||
− | + | ====Supportive medications==== | |
+ | *[[:Category:Steroids|Corticosteroid]] use was left up to physician discretion. It was recommended to not discontinue steroids until at least 6 weeks after radiation therapy. If it was to be discontinued, it should be tapered down gradually over several weeks, or could be titrated down to the lowest tolerated dose. | ||
− | + | '''6-week cycle for up to 12 cycles''' | |
− | |||
===Regimen #2 {{#subobject:75fc7d|Variant=1}}=== | ===Regimen #2 {{#subobject:75fc7d|Variant=1}}=== | ||
Line 166: | Line 200: | ||
''Radiation therapy starts within 6 weeks after surgery.'' | ''Radiation therapy starts within 6 weeks after surgery.'' | ||
+ | ====Radiotherapy==== | ||
*Radiation therapy, 1.8 Gy fractions x 25 fractions, given 5 days per week, total dose of 45 Gy to the planning target volume (PTV-1); then a boost of 1.8 Gy fractions x 8 fractions, given 5 days per week, total boost dose of 14.4 Gy to the PTV-2, for a total cumulative dose of 59.4 Gy | *Radiation therapy, 1.8 Gy fractions x 25 fractions, given 5 days per week, total dose of 45 Gy to the planning target volume (PTV-1); then a boost of 1.8 Gy fractions x 8 fractions, given 5 days per week, total boost dose of 14.4 Gy to the PTV-2, for a total cumulative dose of 59.4 Gy | ||
''Chemotherapy begins within 4 weeks after completion of radiation therapy:'' | ''Chemotherapy begins within 4 weeks after completion of radiation therapy:'' | ||
− | *[[Procarbazine (Matulane)]] 60 mg/ | + | ====Chemotherapy==== |
− | *[[Lomustine (Ceenu)]] 110 mg/ | + | *[[Procarbazine (Matulane)]] 60 mg/m<sup>2</sup> PO once per day on days 8 to 21 |
− | *[[Vincristine (Oncovin)]] 1.4 mg/ | + | *[[Lomustine (Ceenu)]] 110 mg/m<sup>2</sup> PO once on day 1 |
+ | *[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once per day on days 8 & 29 | ||
− | + | ====Supportive medications==== | |
+ | *Antiemetics for [[Lomustine (Ceenu)]]: "[[Domperidone (Motilium)]] or [[Metoclopramide (Reglan)]], and if necessary, [[Ondansetron (Zofran)]] or a similar agent" | ||
+ | *[[:Category:Steroids|Corticosteroids]] kept at lowest possible dose | ||
− | + | '''6-week cycle for 6 cycles''' | |
− | |||
− | |||
===References=== | ===References=== | ||
Line 207: | Line 243: | ||
|- | |- | ||
|} | |} | ||
+ | ====Chemotherapy==== | ||
+ | *[[Temozolomide (Temodar)]] 200 mg/m<sup>2</sup> PO once per day on days 1 to 5 | ||
− | + | '''28-day cycle for 8 cycles''' | |
− | |||
− | '''28-day cycle | ||
''Patients with stable disease or better received '''4 more cycles of temozolomide'''. At time of disease progression patients proceeded to receive [[#Radiation_therapy_2|radiation therapy]].'' | ''Patients with stable disease or better received '''4 more cycles of temozolomide'''. At time of disease progression patients proceeded to receive [[#Radiation_therapy_2|radiation therapy]].'' | ||
Line 230: | Line 266: | ||
''This regimen is meant for patients with 1p/19q loss of heterozygosity (LOH).'' | ''This regimen is meant for patients with 1p/19q loss of heterozygosity (LOH).'' | ||
− | + | ====Chemotherapy==== | |
*[[Temozolomide (Temodar)]] as follows: | *[[Temozolomide (Temodar)]] as follows: | ||
− | **Cycles 1 & 2: 150 mg/ | + | **Cycles 1 & 2: 150 mg/m<sup>2</sup> PO once per day on days 1 to 5, on empty stomach |
− | **Cycle 3 onwards (if no myelosuppression): 200 mg/ | + | **Cycle 3 onwards (if no myelosuppression): 200 mg/m<sup>2</sup> PO once per day on days 1 to 5, on empty stomach |
'''28-day cycles''' | '''28-day cycles''' | ||
− | ===Regimen #3 | + | ===Regimen #3 {{#subobject:f096ab|Variant=1}}=== |
− | + | {| border="1" style="text-align:center;" !align="left" | |
− | <span | + | |'''Study''' |
+ | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
+ | |- | ||
+ | |[http://www.springerlink.com/content/jnn8w15613880103 Taliansky-Aronov et al. 2006] | ||
+ | |<span | ||
style="background:#EEEE00; | style="background:#EEEE00; | ||
padding:3px 6px 3px 6px; | padding:3px 6px 3px 6px; | ||
Line 245: | Line 285: | ||
border-width:2px; | border-width:2px; | ||
border-style:solid;">Non-randomized</span> | border-style:solid;">Non-randomized</span> | ||
+ | |- | ||
+ | |} | ||
+ | ====Chemotherapy==== | ||
+ | *[[Temozolomide (Temodar)]] 200 mg/m<sup>2</sup> PO once per day on days 1 to 5 | ||
− | *[[ | + | ====Supportive medications==== |
+ | *[[:Category:Steroids|Corticosteroids]] could be continued at same dose or reduced, but not increased while on study | ||
'''28-day cycles, given until progression of disease or, in patients with stable disease, up to 24 months''' | '''28-day cycles, given until progression of disease or, in patients with stable disease, up to 24 months''' | ||
− | |||
− | |||
− | |||
===References=== | ===References=== | ||
Line 280: | Line 322: | ||
''This regimen is meant for patients without 1p/19q loss of heterozygosity (LOH).'' | ''This regimen is meant for patients without 1p/19q loss of heterozygosity (LOH).'' | ||
− | + | ====Chemotherapy==== | |
*[[Temozolomide (Temodar)]] as follows: | *[[Temozolomide (Temodar)]] as follows: | ||
− | **Cycles 1 & 2: 150 mg/ | + | **Cycles 1 & 2: 150 mg/m<sup>2</sup> PO once per day on days 1 to 5, on empty stomach |
− | **Cycle 3 onwards (if no myelosuppression): 200 mg/ | + | **Cycle 3 onwards (if no myelosuppression): 200 mg/m<sup>2</sup> PO once per day on days 1 to 5, on empty stomach |
− | '''28-day cycle | + | '''28-day cycle for 2 to 4 cycles, followed by:''' |
+ | ====Chemoradiotherapy==== | ||
+ | *[[Temozolomide (Temodar)]] 75 mg/m<sup>2</sup> PO once per day during radiation therapy | ||
*Concurrent radiation therapy with a total dose of 60 Gy | *Concurrent radiation therapy with a total dose of 60 Gy | ||
− | |||
− | ''' | + | '''One course, followed by:''' |
− | *[[Temozolomide (Temodar)]] 150 to 200 mg/ | + | |
+ | ====Chemotherapy==== | ||
+ | *[[Temozolomide (Temodar)]] 150 to 200 mg/m<sup>2</sup> PO once per day on days 1 to 5, on empty stomach | ||
'''28-day cycles''' | '''28-day cycles''' | ||
Line 305: | Line 350: | ||
|} | |} | ||
===Regimen {{#subobject:a83fc7|Variant=1}}=== | ===Regimen {{#subobject:a83fc7|Variant=1}}=== | ||
− | + | {| border="1" style="text-align:center;" !align="left" | |
− | <span | + | |'''Study''' |
+ | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
+ | |- | ||
+ | |[http://www.springerlink.com/content/7081r46v63261jm4 Chamberlain et al. 2008] | ||
+ | |<span | ||
style="background:#EEEE00; | style="background:#EEEE00; | ||
padding:3px 6px 3px 6px; | padding:3px 6px 3px 6px; | ||
Line 312: | Line 361: | ||
border-width:2px; | border-width:2px; | ||
border-style:solid;">Non-randomized</span> | border-style:solid;">Non-randomized</span> | ||
+ | |- | ||
+ | |} | ||
+ | ====Chemotherapy==== | ||
+ | *[[Bevacizumab (Avastin)]] 10 mg/kg IV over 30 minutes once on day 1 | ||
− | *[[ | + | ====Supportive medications==== |
+ | *Use of [[:Category:Steroids|steroids]] allowed for control of neurologic signs and symptoms | ||
'''14-day cycles''' | '''14-day cycles''' | ||
− | |||
− | |||
− | |||
===References=== | ===References=== | ||
# Chamberlain MC, Johnston S. Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma. J Neurooncol. 2009 Feb;91(3):359-67. Epub 2008 Oct 25. J Neurooncol. 2009 Feb;91(3):359-67. Epub 2008 Oct 25. [http://www.springerlink.com/content/7081r46v63261jm4 link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/18953491 PubMed] | # Chamberlain MC, Johnston S. Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma. J Neurooncol. 2009 Feb;91(3):359-67. Epub 2008 Oct 25. J Neurooncol. 2009 Feb;91(3):359-67. Epub 2008 Oct 25. [http://www.springerlink.com/content/7081r46v63261jm4 link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/18953491 PubMed] | ||
− | # Chamberlain MC, Johnston S. Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma. Cancer. 2009 Apr 15;115(8):1734-43. [http://onlinelibrary.wiley.com/doi/10.1002/cncr.24179/full link to original article] | + | # '''Retrospective:''' Chamberlain MC, Johnston S. Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma. Cancer. 2009 Apr 15;115(8):1734-43. [http://onlinelibrary.wiley.com/doi/10.1002/cncr.24179/full link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/19197992 PubMed] |
==Bevacizumab & Carboplatin {{#subobject:35870a|Regimen=1}}== | ==Bevacizumab & Carboplatin {{#subobject:35870a|Regimen=1}}== | ||
Line 329: | Line 380: | ||
|[[#toc|back to top]] | |[[#toc|back to top]] | ||
|} | |} | ||
− | + | ===Regimen #1 {{#subobject:419b2e|Variant=1}}=== | |
+ | {| border="1" style="text-align:center;" !align="left" | ||
+ | |'''Study''' | ||
+ | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
+ | |- | ||
+ | |[http://journals.lww.com/neurosurgery/pages/articleviewer.aspx?year=2010&issue=07000&article=00013&type=abstract Thompson et al. 2010] | ||
+ | |<span | ||
+ | style="background:#ff0000; | ||
+ | padding:3px 6px 3px 6px; | ||
+ | border-color:black; | ||
+ | border-width:2px; | ||
+ | border-style:solid;">Retrospective</span> | ||
+ | |- | ||
+ | |} | ||
+ | ====Chemotherapy==== | ||
+ | *[[Bevacizumab (Avastin)]] 10 mg/kg IV once on day 1 | ||
+ | *[[Carboplatin (Paraplatin)]] AUC 5 IV once on day 1 | ||
+ | |||
+ | '''28-day cycles''' | ||
+ | |||
+ | ===Regimen #2 {{#subobject:fe380b|Variant=1}}=== | ||
+ | {| border="1" style="text-align:center;" !align="left" | ||
+ | |'''Study''' | ||
+ | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
+ | |- | ||
+ | |[http://www.neurology.org/content/70/10/779.long Norden et al. 2008] | ||
+ | |<span | ||
+ | style="background:#ff0000; | ||
+ | padding:3px 6px 3px 6px; | ||
+ | border-color:black; | ||
+ | border-width:2px; | ||
+ | border-style:solid;">Retrospective</span> | ||
+ | |- | ||
+ | |} | ||
+ | |||
+ | ====Chemotherapy==== | ||
+ | *[[Bevacizumab (Avastin)]] 10 mg/kg IV once every 2 weeks | ||
+ | *[[Carboplatin (Paraplatin)]] AUC 5 to 6 IV (reference does not list schedule of carboplatin) | ||
+ | |||
+ | ===References=== | ||
+ | # '''Retrospective:''' Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, Kesari S, Wen PY. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. 2008 Mar 4;70(10):779-87. [http://www.neurology.org/content/70/10/779.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/18316689 PubMed] | ||
+ | # '''Retrospective:''' Thompson EM, Dosa E, Kraemer DF, Neuwelt EA. Treatment with bevacizumab plus carboplatin for recurrent malignant glioma. Neurosurgery. 2010 Jul;67(1):87-93. [http://journals.lww.com/neurosurgery/pages/articleviewer.aspx?year=2010&issue=07000&article=00013&type=abstract link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/20559095 PubMed] | ||
==Bevacizumab & Irinotecan {{#subobject:6cc49b|Regimen=1}}== | ==Bevacizumab & Irinotecan {{#subobject:6cc49b|Regimen=1}}== | ||
Line 336: | Line 428: | ||
|[[#toc|back to top]] | |[[#toc|back to top]] | ||
|} | |} | ||
− | |||
− | |||
===Regimen {{#subobject:b04dbd|Variant=1}}=== | ===Regimen {{#subobject:b04dbd|Variant=1}}=== | ||
− | + | {| border="1" style="text-align:center;" !align="left" | |
− | <span | + | |'''Study''' |
+ | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
+ | |- | ||
+ | |[http://clincancerres.aacrjournals.org/content/13/4/1253.long Vredenburgh et al. 2007] | ||
+ | |<span | ||
style="background:#EEEE00; | style="background:#EEEE00; | ||
padding:3px 6px 3px 6px; | padding:3px 6px 3px 6px; | ||
Line 346: | Line 440: | ||
border-width:2px; | border-width:2px; | ||
border-style:solid;">Phase II</span> | border-style:solid;">Phase II</span> | ||
− | + | |- | |
− | *[[Irinotecan (Camptosar)]] 125 mg/ | + | |} |
− | **Patients receiving enzyme-inducing antiepileptic drugs (EIAEDs) are treated with a higher dose: | + | ''Note: Vredenburgh et al. 2007 described 6-week cycles in which treatment was every 2 weeks and was otherwise identical, so its entry was consolidated with Taillibert et al. 2009.'' |
− | *[[Bevacizumab (Avastin)]] 10 mg/kg IV once on day 1, given second | + | ====Chemotherapy==== |
+ | *[[Irinotecan (Camptosar)]] 125 mg/m<sup>2</sup> IV over 90 minutes once on day 1, '''given first''' | ||
+ | **Patients receiving enzyme-inducing antiepileptic drugs (EIAEDs) are treated with a higher dose: 340 mg/m<sup>2</sup> IV over 90 minutes once on day 1, '''given first''' | ||
+ | *[[Bevacizumab (Avastin)]] 10 mg/kg IV once on day 1, '''given second''' | ||
**Infusion times for bevacizumab are 90 minutes for the first dose, then if tolerated, 60 minutes for the second dose, and 30 minutes for the third dose and later | **Infusion times for bevacizumab are 90 minutes for the first dose, then if tolerated, 60 minutes for the second dose, and 30 minutes for the third dose and later | ||
− | + | ====Supportive medications==== | |
+ | *"Appropriate antiemetics" | ||
− | + | '''14-day cycles''' | |
− | |||
===References=== | ===References=== | ||
# Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH, Friedman HS. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007 Feb 15;13(4):1253-9. [http://clincancerres.aacrjournals.org/content/13/4/1253.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/17317837 PubMed] | # Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH, Friedman HS. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007 Feb 15;13(4):1253-9. [http://clincancerres.aacrjournals.org/content/13/4/1253.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/17317837 PubMed] | ||
− | # Taillibert S, Vincent LA, Granger B, Marie Y, Carpentier C, Guillevin R, Bellanger A, Mokhtari K, Rousseau A, Psimaras D, Dehais C, Sierra del Rio M, Meng Y, Laigle-Donadey F, Hoang-Xuan K, Sanson M, Delattre JY. Bevacizumab and irinotecan for recurrent oligodendroglial tumors. Neurology. 2009 May 5;72(18):1601-6. [http://www.neurology.org/content/72/18/1601.long link to original article] | + | # '''Retrospective:''' Taillibert S, Vincent LA, Granger B, Marie Y, Carpentier C, Guillevin R, Bellanger A, Mokhtari K, Rousseau A, Psimaras D, Dehais C, Sierra del Rio M, Meng Y, Laigle-Donadey F, Hoang-Xuan K, Sanson M, Delattre JY. Bevacizumab and irinotecan for recurrent oligodendroglial tumors. Neurology. 2009 May 5;72(18):1601-6. [http://www.neurology.org/content/72/18/1601.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/19414728 PubMed] |
==Cyclophosphamide (Cytoxan) {{#subobject:270740|Regimen=1}}== | ==Cyclophosphamide (Cytoxan) {{#subobject:270740|Regimen=1}}== | ||
Line 367: | Line 464: | ||
|} | |} | ||
===Regimen {{#subobject:cd7eda|Variant=1}}=== | ===Regimen {{#subobject:cd7eda|Variant=1}}=== | ||
− | + | {| border="1" style="text-align:center;" !align="left" | |
− | <span | + | |'''Study''' |
+ | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
+ | |- | ||
+ | |[http://onlinelibrary.wiley.com/doi/10.1002/cncr.21582/full Chamberlain et al. 2006] | ||
+ | |<span | ||
style="background:#EEEE00; | style="background:#EEEE00; | ||
padding:3px 6px 3px 6px; | padding:3px 6px 3px 6px; | ||
Line 374: | Line 475: | ||
border-width:2px; | border-width:2px; | ||
border-style:solid;">Phase II</span> | border-style:solid;">Phase II</span> | ||
+ | |- | ||
+ | |} | ||
+ | ====Chemotherapy==== | ||
+ | *[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1 & 2 | ||
− | + | ====Supportive medications==== | |
− | |||
− | |||
− | |||
− | Supportive medications | ||
*[[Dexamethasone (Decadron)]] allowed for control of neurologic symptoms | *[[Dexamethasone (Decadron)]] allowed for control of neurologic symptoms | ||
− | *Ondansetron (Zofran) 0.15 mg/kg IV once prior to cyclophosphamide | + | *[[Ondansetron (Zofran)]] 0.15 mg/kg IV once prior to cyclophosphamide |
*[[Dexamethasone (Decadron)]] 4 mg IV once prior to cyclophosphamide | *[[Dexamethasone (Decadron)]] 4 mg IV once prior to cyclophosphamide | ||
*1 liter normal saline IV over 2 hours prior to cyclophosphamide | *1 liter normal saline IV over 2 hours prior to cyclophosphamide | ||
− | *Prochlorperazine (Compazine) (dose/schedule not specified) prn nausea/vomiting | + | *[[Prochlorperazine (Compazine)]] (dose/schedule not specified) prn nausea/vomiting |
+ | |||
+ | '''28-day cycles''' | ||
===References=== | ===References=== | ||
Line 395: | Line 498: | ||
|} | |} | ||
===Regimen {{#subobject:9960a7|Variant=1}}=== | ===Regimen {{#subobject:9960a7|Variant=1}}=== | ||
− | + | {| border="1" style="text-align:center;" !align="left" | |
− | <span | + | |'''Study''' |
+ | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
+ | |- | ||
+ | |[http://link.springer.com/article/10.1007/BF00177478 Fulton et al. 1996] | ||
+ | |<span | ||
style="background:#EEEE00; | style="background:#EEEE00; | ||
padding:3px 6px 3px 6px; | padding:3px 6px 3px 6px; | ||
Line 402: | Line 509: | ||
border-width:2px; | border-width:2px; | ||
border-style:solid;">Phase II</span> | border-style:solid;">Phase II</span> | ||
− | + | |- | |
+ | |} | ||
+ | ====Chemotherapy==== | ||
*[[Etoposide (Vepesid)]] 50 mg PO once per day | *[[Etoposide (Vepesid)]] 50 mg PO once per day | ||
− | ''' | + | '''Given until progression of disease or unacceptable toxicity''' |
===References=== | ===References=== | ||
Line 415: | Line 524: | ||
|[[#toc|back to top]] | |[[#toc|back to top]] | ||
|} | |} | ||
− | |||
− | ===Regimen {{#subobject:31e6bc|Variant=1}}=== | + | ===Regimen #1 {{#subobject:31e6bc|Variant=1}}=== |
− | + | {| border="1" style="text-align:center;" !align="left" | |
− | <span | + | |'''Study''' |
+ | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
+ | |- | ||
+ | |[http://onlinelibrary.wiley.com/doi/10.1002/cncr.23404/full Chamberlain et al. 2008] | ||
+ | |<span | ||
style="background:#EEEE00; | style="background:#EEEE00; | ||
padding:3px 6px 3px 6px; | padding:3px 6px 3px 6px; | ||
Line 425: | Line 537: | ||
border-width:2px; | border-width:2px; | ||
border-style:solid;">Phase II</span> | border-style:solid;">Phase II</span> | ||
+ | |- | ||
+ | |} | ||
+ | ====Chemotherapy==== | ||
+ | *[[Irinotecan (Camptosar)]] 350 mg/m<sup>2</sup> IV over 120 minutes once on day 1 | ||
+ | **Patients receiving enzyme-inducing antiepileptic drugs (EIAEDs) are treated with a higher dose: 600 mg/m<sup>2</sup> IV over 120 minutes once on day 1 | ||
− | *[[ | + | ====Supportive medications==== |
− | ** | + | *[[Dexamethasone (Decadron)]] allowed for control of neurologic symptoms |
+ | *500 mL normal saline IV over 1 hour prior to irinotecan | ||
+ | *Intravenous [[Ondansetron (Zofran)]], [[Granisetron (Kytril)]], or [[Dolasetron (Anzemet)]] as [[Antiemesis|antiemetic]] prior to irinotecan | ||
+ | *[[Dexamethasone (Decadron)]] 20 mg IV once prior to irinotecan | ||
+ | *[[Atropine (Atropen)]] 0.5 mg IV once prior to irinotecan | ||
+ | *[[Prochlorperazine (Compazine)]] (dose/schedule not specified) prn nausea/vomiting | ||
+ | *[[Loperamide (Imodium)]] (dose/schedule not specified) prn diarrhea | ||
'''21-day cycles''' | '''21-day cycles''' | ||
− | + | ===Regimen #2 {{#subobject:2512a2|Variant=1}}=== | |
− | + | {| border="1" style="text-align:center;" !align="left" | |
− | + | |'''Study''' | |
− | + | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | |
− | *[[ | + | |- |
− | * | + | |[http://jco.ascopubs.org/content/17/5/1516.long Friedman et al. 1999] |
− | * | + | |<span |
− | * | + | style="background:#EEEE00; |
+ | padding:3px 6px 3px 6px; | ||
+ | border-color:black; | ||
+ | border-width:2px; | ||
+ | border-style:solid;">Phase II</span> | ||
+ | |- | ||
+ | |} | ||
+ | ====Chemotherapy==== | ||
+ | *[[Irinotecan (Camptosar)]] 125 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22 | ||
+ | **If tolerated, dose could be increased to 150 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22 | ||
+ | |||
+ | ====Supportive medications==== | ||
+ | *[[Steroid conversions|Steroids]] at lowest dose necessary | ||
+ | *Avoid laxatives and magnesium-containing antacids due to potential for diarrhea | ||
+ | |||
+ | '''42-day (6-week) cycles, given until progression of disease or unacceptable toxicity''' | ||
===References=== | ===References=== | ||
− | # Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent oligodendrogliomas. J Neurooncol. 2002 Sep;59(2):157-63. [http://link.springer.com/article/10.1023/A%3A1019608404378 link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/12241109 PubMed] | + | # Friedman HS, Petros WP, Friedman AH, Schaaf LJ, Kerby T, Lawyer J, Parry M, Houghton PJ, Lovell S, Rasheed K, Cloughsey T, Stewart ES, Colvin OM, Provenzale JM, McLendon RE, Bigner DD, Cokgor I, Haglund M, Rich J, Ashley D, Malczyn J, Elfring GL, Miller LL. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol. 1999 May;17(5):1516-25. [http://jco.ascopubs.org/content/17/5/1516.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/10334539 PubMed] |
+ | # '''Phase I:''' Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent oligodendrogliomas. J Neurooncol. 2002 Sep;59(2):157-63. [http://link.springer.com/article/10.1023/A%3A1019608404378 link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/12241109 PubMed] | ||
# Chamberlain MC, Wei-Tsao DD, Blumenthal DT, Glantz MJ. Salvage chemotherapy with CPT-11 for recurrent temozolomide-refractory anaplastic astrocytoma. Cancer. 2008 May 1;112(9):2038-45. [http://onlinelibrary.wiley.com/doi/10.1002/cncr.23404/full link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/18361434 PubMed] | # Chamberlain MC, Wei-Tsao DD, Blumenthal DT, Glantz MJ. Salvage chemotherapy with CPT-11 for recurrent temozolomide-refractory anaplastic astrocytoma. Cancer. 2008 May 1;112(9):2038-45. [http://onlinelibrary.wiley.com/doi/10.1002/cncr.23404/full link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/18361434 PubMed] | ||
Line 449: | Line 588: | ||
|[[#toc|back to top]] | |[[#toc|back to top]] | ||
|} | |} | ||
− | *Note: The NCCN, Central Nervous System Cancers version 1.2013 lists this regimen (Wick et al. 2010) with [[#Lomustine_.28Ceenu.29_2|Lomustine (Ceenu) salvage therapy in glioblastoma multiforme]] as an option for treatment of anaplastic gliomas. | + | *Note: The NCCN, Central Nervous System Cancers version 1.2013 lists this regimen (Wick et al. 2010) with [[#Lomustine_.28Ceenu.29_2|Lomustine (Ceenu) salvage therapy in glioblastoma multiforme]] as an option for treatment of anaplastic gliomas. This study only included patients who had histologically confirmed WHO grade 4 glioblastoma. The NCCN also listed the following phase II trial as a reference for use of Carmustine (BiCNU)/Lomustine (Ceenu) in recurrent malignant glioma, but the nitrosourea used was fotemustine (FTM): R. Soffietti, R. Rudà, E. Trevisan, E. Picco, D. Guarneri, M. Caroli, M. Fabrini, V. Scotti. Phase II study of bevacizumab and nitrosourea in patients with recurrent malignant glioma: A multicenter Italian study. CNS Tumors 2012 J Clin Oncol 27:15s, 2009 (suppl; abstr 2012). 2009 ASCO Annual Meeting abstract 2012. [https://meetinglibrary.asco.org/content/32821-65 link to abstract] |
==PCV {{#subobject:1d08ed|Regimen=1}}== | ==PCV {{#subobject:1d08ed|Regimen=1}}== | ||
Line 475: | Line 614: | ||
|} | |} | ||
''All patients had progressed after previously receiving [[#Radiation_therapy|radiation therapy]], [[#Temozolomide_.28Temodar.29_2|salvage temozolomide]], or [[#Radiation_therapy_2|salvage radiation therapy]].'' | ''All patients had progressed after previously receiving [[#Radiation_therapy|radiation therapy]], [[#Temozolomide_.28Temodar.29_2|salvage temozolomide]], or [[#Radiation_therapy_2|salvage radiation therapy]].'' | ||
− | *[[Procarbazine (Matulane)]] 60 mg/ | + | ====Chemotherapy==== |
− | *[[Lomustine (Ceenu)]] 110 mg/ | + | *[[Procarbazine (Matulane)]] 60 mg/m<sup>2</sup> PO once per day on days 8 to 21 |
+ | *[[Lomustine (Ceenu)]] 110 mg/m<sup>2</sup> PO once on day 1 | ||
*[[Vincristine (Oncovin)]] 2 mg IV once per day on days 8 & 29 | *[[Vincristine (Oncovin)]] 2 mg IV once per day on days 8 & 29 | ||
Line 483: | Line 623: | ||
''At progression, patients who had not previously received temozolomide proceeded to receive [[#Temozolomide_.28Temodar.29_2|salvage temozolomide]].'' | ''At progression, patients who had not previously received temozolomide proceeded to receive [[#Temozolomide_.28Temodar.29_2|salvage temozolomide]].'' | ||
− | ===Regimen # | + | ===Regimen #2 {{#subobject:d8f8c2|Variant=1}}=== |
− | + | {| border="1" style="text-align:center;" !align="left" | |
− | <span | + | |'''Study''' |
+ | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
+ | |- | ||
+ | |[http://www.ncbi.nlm.nih.gov/pubmed/7407756 Levin et al. 1980] | ||
+ | |<span | ||
style="background:#EEEE00; | style="background:#EEEE00; | ||
padding:3px 6px 3px 6px; | padding:3px 6px 3px 6px; | ||
Line 491: | Line 635: | ||
border-width:2px; | border-width:2px; | ||
border-style:solid;">Non-randomized</span> | border-style:solid;">Non-randomized</span> | ||
− | + | |- | |
− | *[[Procarbazine (Matulane)]] 60 mg/ | + | |} |
− | *[[Lomustine (Ceenu)]] 110 mg/ | + | ====Chemotherapy==== |
− | *[[Vincristine (Oncovin)]] 1.4 mg/ | + | *[[Procarbazine (Matulane)]] 60 mg/m<sup>2</sup> PO once per day on days 8 to 21 |
+ | *[[Lomustine (Ceenu)]] 110 mg/m<sup>2</sup> PO once on day 1 | ||
+ | *[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once per day on days 8 & 29 | ||
'''6-week cycles, given until progression of disease or unacceptable toxicity''' | '''6-week cycles, given until progression of disease or unacceptable toxicity''' | ||
− | ===Regimen # | + | ===Regimen #3, higher doses {{#subobject:eacf9b|Variant=1}}=== |
− | + | {| border="1" style="text-align:center;" !align="left" | |
− | <span | + | |'''Study''' |
+ | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
+ | |- | ||
+ | |[http://jco.ascopubs.org/content/12/10/2013.long Cairncross et al. 1994] | ||
+ | |<span | ||
style="background:#EEEE00; | style="background:#EEEE00; | ||
padding:3px 6px 3px 6px; | padding:3px 6px 3px 6px; | ||
Line 506: | Line 656: | ||
border-width:2px; | border-width:2px; | ||
border-style:solid;">Phase II</span> | border-style:solid;">Phase II</span> | ||
− | + | |- | |
− | *[[Procarbazine (Matulane)]] 75 mg/ | + | |} |
− | *[[Lomustine (Ceenu)]] 130 mg/ | + | ====Chemotherapy==== |
− | *[[Vincristine (Oncovin)]] 1.4 mg/ | + | *[[Procarbazine (Matulane)]] 75 mg/m<sup>2</sup> PO once per day on days 8 to 21 |
+ | *[[Lomustine (Ceenu)]] 130 mg/m<sup>2</sup> PO once on day 1 | ||
+ | *[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (dose not capped) IV once per day on days 8 & 29 | ||
'''6-week cycles, given until progression of disease or unacceptable toxicity''' | '''6-week cycles, given until progression of disease or unacceptable toxicity''' | ||
Line 543: | Line 695: | ||
''Patients had previously received [[#PCV|PCV]] versus [[#Temozolomide_.28Temodar.29|temozolomide]] prior to progression.'' | ''Patients had previously received [[#PCV|PCV]] versus [[#Temozolomide_.28Temodar.29|temozolomide]] prior to progression.'' | ||
− | + | ====Radiotherapy==== | |
*Radiation therapy with 1.8 to 2 Gy fractions given over 6 weeks for a total dose of 60 Gy | *Radiation therapy with 1.8 to 2 Gy fractions given over 6 weeks for a total dose of 60 Gy | ||
Line 574: | Line 726: | ||
|} | |} | ||
''All patients had progressed after previously receiving [[#Radiation_therapy|radiation therapy]], [[#PCV_2|salvage PCV]], or [[#Radiation_therapy_2|salvage radiation therapy]].'' | ''All patients had progressed after previously receiving [[#Radiation_therapy|radiation therapy]], [[#PCV_2|salvage PCV]], or [[#Radiation_therapy_2|salvage radiation therapy]].'' | ||
− | + | ====Chemotherapy==== | |
− | *[[Temozolomide (Temodar)]] 200 mg/ | + | *[[Temozolomide (Temodar)]] 200 mg/m<sup>2</sup> PO once per day on days 1 to 5 |
'''28-day cycles until progression''' | '''28-day cycles until progression''' | ||
Line 581: | Line 733: | ||
''At progression, patients who had not previously received PCV proceeded to receive [[#PCV_2|salvage PCV]].'' | ''At progression, patients who had not previously received PCV proceeded to receive [[#PCV_2|salvage PCV]].'' | ||
− | ===Regimen #2, | + | ===Regimen #2, continuous therapy {{#subobject:276de1|Variant=1}}=== |
− | + | {| border="1" style="text-align:center;" !align="left" | |
− | <span | + | |'''Study''' |
+ | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
+ | |- | ||
+ | |[http://onlinelibrary.wiley.com/doi/10.1002/cncr.23813/full Perry et al. 2008 (RESCUE)] | ||
+ | |<span | ||
style="background:#EEEE00; | style="background:#EEEE00; | ||
padding:3px 6px 3px 6px; | padding:3px 6px 3px 6px; | ||
Line 589: | Line 745: | ||
border-width:2px; | border-width:2px; | ||
border-style:solid;">Phase II</span> | border-style:solid;">Phase II</span> | ||
+ | |- | ||
+ | |} | ||
+ | ''Patients who undergo conventional temozolomide therapy, have surgery and radiation therapy, and then relapse receive:'' | ||
+ | ====Chemotherapy==== | ||
+ | *[[Temozolomide (Temodar)]] 150 to 200 mg/m<sup>2</sup> PO once per day on days 1 to 5 | ||
− | + | '''28-day cycles''' | |
− | |||
− | ''' | + | ''Patients with progressive disease are changed to:'' |
+ | *[[Temozolomide (Temodar)]] 50 mg/m<sup>2</sup> PO once per day, taken continuously without treatment break | ||
− | + | '''Given until progression of disease or unacceptable toxicity''' | |
− | |||
− | ''' | + | ===Regimen #3, traditional dosing {{#subobject:1839a1|Variant=1}}=== |
+ | {| border="1" style="text-align:center;" !align="left" | ||
+ | |'''Study''' | ||
+ | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
+ | |- | ||
+ | |[http://onlinelibrary.wiley.com/doi/10.1002/cncr.22961/full Nicholson et al. 2007] | ||
+ | |<span | ||
+ | style="background:#EEEE00; | ||
+ | padding:3px 6px 3px 6px; | ||
+ | border-color:black; | ||
+ | border-width:2px; | ||
+ | border-style:solid;">Non-randomized</span> | ||
+ | |- | ||
+ | |} | ||
+ | ====Chemotherapy==== | ||
+ | *[[Temozolomide (Temodar)]] 200 mg/m<sup>2</sup> PO once per day on days 1 to 5 | ||
+ | **Patients who previously received craniospinal irradiation (CSI) instead received 180 mg/m<sup>2</sup> PO once per day on days 1 to 5 | ||
− | + | '''28-day cycle for up to 11 cycles''' | |
− | |||
− | ===Regimen #4 | + | ===Regimen #4 {{#subobject:52f20c|Variant=1}}=== |
− | + | {| border="1" style="text-align:center;" !align="left" | |
− | <span | + | |'''Study''' |
+ | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
+ | |- | ||
+ | |[http://jco.ascopubs.org/content/17/9/2762.long Yung et al. 1999] | ||
+ | |<span | ||
style="background:#EEEE00; | style="background:#EEEE00; | ||
padding:3px 6px 3px 6px; | padding:3px 6px 3px 6px; | ||
Line 611: | Line 790: | ||
border-width:2px; | border-width:2px; | ||
border-style:solid;">Phase II</span> | border-style:solid;">Phase II</span> | ||
+ | |- | ||
+ | |} | ||
− | *Patients who had never previously received chemotherapy: | + | ====Chemotherapy==== |
− | *Patients who previously received chemotherapy started with | + | *[[Temozolomide (Temodar)]] as follows: |
− | + | **Patients who had never previously received chemotherapy: 200 mg/m<sup>2</sup> PO once per day on days 1 to 5 | |
− | + | **Patients who previously received chemotherapy started with 150 mg/m<sup>2</sup> PO once per day on days 1 to 5, which could be increased as tolerated to 200 mg/m<sup>2</sup> PO once per day on days 1 to 5 | |
− | Supportive medications | + | ====Supportive medications==== |
*Prophylactic [[antiemesis|antiemetics]] as needed | *Prophylactic [[antiemesis|antiemetics]] as needed | ||
*Lowest dose of [[Steroid conversions|corticosteroids]] necessary to maintain neurologic stability | *Lowest dose of [[Steroid conversions|corticosteroids]] necessary to maintain neurologic stability | ||
+ | |||
+ | '''28-day cycle for up to 2 years''' | ||
===References=== | ===References=== | ||
# Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, Albright R, Olson J, Chang SM, O'Neill AM, Friedman AH, Bruner J, Yue N, Dugan M, Zaknoen S, Levin VA. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol. 1999 Sep;17(9):2762-71. [http://jco.ascopubs.org/content/17/9/2762.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/10561351 PubMed] | # Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, Albright R, Olson J, Chang SM, O'Neill AM, Friedman AH, Bruner J, Yue N, Dugan M, Zaknoen S, Levin VA. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol. 1999 Sep;17(9):2762-71. [http://jco.ascopubs.org/content/17/9/2762.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/10561351 PubMed] | ||
+ | # Nicholson HS, Kretschmar CS, Krailo M, Bernstein M, Kadota R, Fort D, Friedman H, Harris MB, Tedeschi-Blok N, Mazewski C, Sato J, Reaman GH. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer. 2007 Oct 1;110(7):1542-50. [http://onlinelibrary.wiley.com/doi/10.1002/cncr.22961/full link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/17705175 PubMed] | ||
# Perry JR, Rizek P, Cashman R, Morrison M, Morrison T. Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach. Cancer. 2008 Oct 15;113(8):2152-7. [http://onlinelibrary.wiley.com/doi/10.1002/cncr.23813/full link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/18756530 PubMed] | # Perry JR, Rizek P, Cashman R, Morrison M, Morrison T. Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach. Cancer. 2008 Oct 15;113(8):2152-7. [http://onlinelibrary.wiley.com/doi/10.1002/cncr.23813/full link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/18756530 PubMed] | ||
## '''Update:''' Perry JR, Bélanger K, Mason WP, Fulton D, Kavan P, Easaw J, Shields C, Kirby S, Macdonald DR, Eisenstat DD, Thiessen B, Forsyth P, Pouliot JF. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol. 2010 Apr 20;28(12):2051-7. Epub 2010 Mar 22. [http://jco.ascopubs.org/content/28/12/2051.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/20308655 PubMed] | ## '''Update:''' Perry JR, Bélanger K, Mason WP, Fulton D, Kavan P, Easaw J, Shields C, Kirby S, Macdonald DR, Eisenstat DD, Thiessen B, Forsyth P, Pouliot JF. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol. 2010 Apr 20;28(12):2051-7. Epub 2010 Mar 22. [http://jco.ascopubs.org/content/28/12/2051.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/20308655 PubMed] | ||
Line 679: | Line 863: | ||
|} | |} | ||
+ | ====Radiotherapy==== | ||
*Radiation therapy starting within 3 weeks after surgical resection, with one of the following: | *Radiation therapy starting within 3 weeks after surgical resection, with one of the following: | ||
**Whole brain: 172 cGy (rads) fractions x 35 fractions, given over 7 weeks for a total dose of 6020 cGy (6020 rads/~1700 rets) | **Whole brain: 172 cGy (rads) fractions x 35 fractions, given over 7 weeks for a total dose of 6020 cGy (6020 rads/~1700 rets) | ||
**Whole brain & cone down: 172 cGy (rads) fractions x 25 fractions, given over 5 weeks for a total dose of 4300 cGy (4300 rads), then coned-down boost of 172 cGy (rads) fractions x 10 fractions, given over 2 weeks for a dose of 1720 cGy (rads), and a total cumulative dose of 6020 cGy (rads) | **Whole brain & cone down: 172 cGy (rads) fractions x 25 fractions, given over 5 weeks for a total dose of 4300 cGy (4300 rads), then coned-down boost of 172 cGy (rads) fractions x 10 fractions, given over 2 weeks for a dose of 1720 cGy (rads), and a total cumulative dose of 6020 cGy (rads) | ||
− | + | ''One course, followed by:'' | |
− | *[[Carmustine (BiCNU)]] 80 mg/ | + | ====Chemotherapy==== |
+ | *[[Carmustine (BiCNU)]] 80 mg/m<sup>2</sup> IV over 30 to 60 minutes once per day on days 1 to 3 | ||
− | '''8-week cycles, with no more than a maximum total dose of 1500 mg/ | + | '''8-week cycles, with no more than a maximum total dose of 1500 mg/m<sup>2</sup> [[Carmustine (BiCNU)]] given''' |
Supportive care: | Supportive care: | ||
− | *Pulmonary function tests (PFTs) checked before start of therapy, and then when cumulative dose of [[Carmustine (BiCNU)]] reaches 800 mg/ | + | *Pulmonary function tests (PFTs) checked before start of therapy, and then when cumulative dose of [[Carmustine (BiCNU)]] reaches 800 mg/m<sup>2</sup> and 1200 mg/m<sup>2</sup> |
===References=== | ===References=== | ||
Line 733: | Line 919: | ||
|- | |- | ||
|} | |} | ||
− | + | ====Chemoradiotherapy==== | |
− | ==== | + | *[[Temozolomide (Temodar)]] 75 mg/m<sup>2</sup> PO once per day, used starting the first day of radiation therapy until the last day of radiation therapy, and no longer than 49 days |
*Concurrent radiation therapy, 2 Gy fractions x 30 fractions given 5 days per week, for a total dose of 60 Gy | *Concurrent radiation therapy, 2 Gy fractions x 30 fractions given 5 days per week, for a total dose of 60 Gy | ||
− | |||
− | Supportive medications | + | ====Supportive medications==== |
*PCP prophylaxis with one of the following: | *PCP prophylaxis with one of the following: | ||
**[[Trimethoprim/Sulfamethoxazole (Bactrim DS)|Trimethoprim/Sulfamethoxazole (Bactrim)]] | **[[Trimethoprim/Sulfamethoxazole (Bactrim DS)|Trimethoprim/Sulfamethoxazole (Bactrim)]] | ||
Line 750: | Line 935: | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Temozolomide (Temodar)]] as follows: | *[[Temozolomide (Temodar)]] as follows: | ||
− | **Cycle 1: 150 mg/ | + | **Cycle 1: 150 mg/m<sup>2</sup> PO once per day on days 1 to 5 |
− | **If tolerated, in cycles 2 to 6: 200 mg/ | + | **If tolerated, in cycles 2 to 6: 200 mg/m<sup>2</sup> PO once per day on days 1 to 5 |
− | Supportive medications | + | ====Supportive medications==== |
*[[Metoclopramide (Reglan)]] or [[Antiemesis|5-HT3 antagonist]] required | *[[Metoclopramide (Reglan)]] or [[Antiemesis|5-HT3 antagonist]] required | ||
− | '''28-day cycle | + | '''28-day cycle for 6 cycles''' |
===References=== | ===References=== | ||
Line 770: | Line 955: | ||
|[[#toc|back to top]] | |[[#toc|back to top]] | ||
|} | |} | ||
− | ===Regimen #1 | + | ===Regimen #1 {{#subobject:c6f29b|Variant=1}}=== |
− | + | {| border="1" style="text-align:center;" !align="left" | |
− | <span | + | |'''Study''' |
− | style="background:# | + | |[[Levels_of_Evidence#Evidence|'''Evidence''']] |
+ | |'''Comparator''' | ||
+ | |- | ||
+ | |[http://jco.ascopubs.org/content/27/28/4733.long Friedman et al. 2009] | ||
+ | |<span | ||
+ | style="background:#00cd00; | ||
padding:3px 6px 3px 6px; | padding:3px 6px 3px 6px; | ||
border-color:black; | border-color:black; | ||
border-width:2px; | border-width:2px; | ||
− | border-style:solid;">Phase II</span> | + | border-style:solid;">Randomized Phase II</span> |
− | + | |[[#Bevacizumab_.26_Irinotecan_2|Bevacizumab & Irinotecan]] | |
+ | |- | ||
+ | |} | ||
+ | ====Chemotherapy==== | ||
*[[Bevacizumab (Avastin)]] 10 mg/kg IV once per day on days 1, 15, 29 | *[[Bevacizumab (Avastin)]] 10 mg/kg IV once per day on days 1, 15, 29 | ||
− | '''6-week | + | '''6-week cycle for up to 104 weeks, until progression of disease, or unacceptable toxicity''' |
− | ===Regimen #2 | + | ===Regimen #2 {{#subobject:35ed36|Variant=1}}=== |
− | + | {| border="1" style="text-align:center;" !align="left" | |
− | <span | + | |'''Study''' |
+ | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
+ | |- | ||
+ | |[http://jco.ascopubs.org/content/27/5/740.long Kreisl et al. 2008] | ||
+ | |<span | ||
style="background:#EEEE00; | style="background:#EEEE00; | ||
padding:3px 6px 3px 6px; | padding:3px 6px 3px 6px; | ||
Line 791: | Line 988: | ||
border-width:2px; | border-width:2px; | ||
border-style:solid;">Phase II</span> | border-style:solid;">Phase II</span> | ||
− | + | |- | |
+ | |} | ||
+ | ====Chemotherapy==== | ||
*[[Bevacizumab (Avastin)]] 10 mg/kg IV once per day on days 1 & 15 | *[[Bevacizumab (Avastin)]] 10 mg/kg IV once per day on days 1 & 15 | ||
− | '''4-week cycles, given until progression of disease, or unacceptable toxicity'''; upon progression, patients | + | '''4-week cycles, given until progression of disease, or unacceptable toxicity'''; upon progression, patients received [[#Irinotecan_.28Camptosar.29_.26_Bevacizumab_.28Avastin.29_2|Irinotecan (Camptosar) & Bevacizumab (Avastin)]] |
===References=== | ===References=== | ||
− | # Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS, Fine HA. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009 Feb 10;27(5):740-5 | + | # Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS, Fine HA. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009 Feb 10;27(5):740-5. Epub 2008 Dec 29. [http://jco.ascopubs.org/content/27/5/740.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/19114704 PubMed] |
+ | <!-- Presented in part at the 12th Annual Meeting of the Society for Neuro-Oncology, November 15-18, 2007, Dallas, TX, and at the 44th Annual Meeting of the American Society of Clinical Oncology, May 30-June 3, 2008, Chicago, IL. --> | ||
# Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009 Oct 1;27(28):4733-40. Epub 2009 Aug 31. [http://jco.ascopubs.org/content/27/28/4733.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/19720927 PubMed] | # Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009 Oct 1;27(28):4733-40. Epub 2009 Aug 31. [http://jco.ascopubs.org/content/27/28/4733.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/19720927 PubMed] | ||
Line 805: | Line 1,005: | ||
|[[#toc|back to top]] | |[[#toc|back to top]] | ||
|} | |} | ||
− | ===Regimen #1 | + | ===Regimen #1 {{#subobject:401e2e|Variant=1}}=== |
− | + | {| border="1" style="text-align:center;" !align="left" | |
− | <span | + | |'''Study''' |
+ | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
+ | |- | ||
+ | |[http://journals.lww.com/neurosurgery/pages/articleviewer.aspx?year=2010&issue=07000&article=00013&type=abstract Thompson et al. 2010] | ||
+ | |<span | ||
style="background:#ff0000; | style="background:#ff0000; | ||
padding:3px 6px 3px 6px; | padding:3px 6px 3px 6px; | ||
Line 813: | Line 1,017: | ||
border-width:2px; | border-width:2px; | ||
border-style:solid;">Retrospective</span> | border-style:solid;">Retrospective</span> | ||
− | + | |- | |
+ | |} | ||
+ | ====Chemotherapy==== | ||
+ | *[[Bevacizumab (Avastin)]] 10 mg/kg IV once on day 1 | ||
*[[Carboplatin (Paraplatin)]] AUC 5 IV once on day 1 | *[[Carboplatin (Paraplatin)]] AUC 5 IV once on day 1 | ||
− | |||
'''28-day cycles''' | '''28-day cycles''' | ||
− | ===Regimen #2 | + | ===Regimen #2 {{#subobject:ffa90b|Variant=1}}=== |
− | + | {| border="1" style="text-align:center;" !align="left" | |
− | <span | + | |'''Study''' |
+ | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
+ | |- | ||
+ | |[http://www.neurology.org/content/70/10/779.long Norden et al. 2008] | ||
+ | |<span | ||
style="background:#ff0000; | style="background:#ff0000; | ||
padding:3px 6px 3px 6px; | padding:3px 6px 3px 6px; | ||
Line 827: | Line 1,037: | ||
border-width:2px; | border-width:2px; | ||
border-style:solid;">Retrospective</span> | border-style:solid;">Retrospective</span> | ||
+ | |- | ||
+ | |} | ||
− | + | ====Chemotherapy==== | |
*[[Bevacizumab (Avastin)]] 10 mg/kg IV once every 2 weeks | *[[Bevacizumab (Avastin)]] 10 mg/kg IV once every 2 weeks | ||
+ | *[[Carboplatin (Paraplatin)]] AUC 5 to 6 IV (reference does not list schedule of carboplatin) | ||
===References=== | ===References=== | ||
− | # Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, Kesari S, Wen PY. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. 2008 Mar 4;70(10):779-87. [http://www.neurology.org/content/70/10/779.long link to original article] | + | # '''Retrospective:''' Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, Kesari S, Wen PY. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. 2008 Mar 4;70(10):779-87. [http://www.neurology.org/content/70/10/779.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/18316689 PubMed] |
− | # Thompson EM, Dosa E, Kraemer DF, Neuwelt EA. Treatment with bevacizumab plus carboplatin for recurrent malignant glioma. Neurosurgery. 2010 Jul;67(1):87-93. [http://journals.lww.com/neurosurgery/pages/articleviewer.aspx?year=2010&issue=07000&article=00013&type=abstract link to original article] | + | # '''Retrospective:''' Thompson EM, Dosa E, Kraemer DF, Neuwelt EA. Treatment with bevacizumab plus carboplatin for recurrent malignant glioma. Neurosurgery. 2010 Jul;67(1):87-93. [http://journals.lww.com/neurosurgery/pages/articleviewer.aspx?year=2010&issue=07000&article=00013&type=abstract link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/20559095 PubMed] |
==Bevacizumab & Irinotecan {{#subobject:a9cf4a|Regimen=1}}== | ==Bevacizumab & Irinotecan {{#subobject:a9cf4a|Regimen=1}}== | ||
Line 840: | Line 1,053: | ||
|[[#toc|back to top]] | |[[#toc|back to top]] | ||
|} | |} | ||
− | ===Regimen #1, | + | ===Regimen #1, every 2 week schedule {{#subobject:a156f1|Variant=1}}=== |
− | + | {| border="1" style="text-align:center;" !align="left" | |
− | <span | + | |'''Study''' |
− | style="background:# | + | |[[Levels_of_Evidence#Evidence|'''Evidence''']] |
+ | |'''Comparator''' | ||
+ | |- | ||
+ | |[http://jco.ascopubs.org/content/25/30/4714.long Chen et al. 2007] | ||
+ | |<span | ||
+ | style="background:#eeee00; | ||
+ | padding:3px 6px 3px 6px; | ||
+ | border-color:black; | ||
+ | border-width:2px; | ||
+ | border-style:solid;">Pilot, >20 pts</span> | ||
+ | | | ||
+ | |- | ||
+ | |[http://jco.ascopubs.org/content/25/30/4722.long Vredenburgh et al. 2007] | ||
+ | |<span | ||
+ | style="background:#eeee00; | ||
+ | padding:3px 6px 3px 6px; | ||
+ | border-color:black; | ||
+ | border-width:2px; | ||
+ | border-style:solid;">Phase II</span> | ||
+ | | | ||
+ | |- | ||
+ | |[http://www.neurology.org/content/70/10/779.long Norden et al. 2008] | ||
+ | |<span | ||
+ | style="background:#eeee00; | ||
padding:3px 6px 3px 6px; | padding:3px 6px 3px 6px; | ||
border-color:black; | border-color:black; | ||
border-width:2px; | border-width:2px; | ||
border-style:solid;">Phase II</span> | border-style:solid;">Phase II</span> | ||
+ | | | ||
+ | |- | ||
+ | |[http://jco.ascopubs.org/content/27/28/4733.long Friedman et al. 2009] | ||
+ | |<span | ||
+ | style="background:#00cd00; | ||
+ | padding:3px 6px 3px 6px; | ||
+ | border-color:black; | ||
+ | border-width:2px; | ||
+ | border-style:solid;">Randomized Phase II</span> | ||
+ | |[[#Bevacizumab_.28Avastin.29_2|Bevacizumab]] | ||
+ | |- | ||
+ | |} | ||
− | *[[Irinotecan (Camptosar)]] 125 mg/ | + | ''Note: Friedman et al. 2009 described 6-week cycles in which treatment was every 2 weeks, given up to 104 weeks, and was otherwise identical, so its entry was consolidated with the other ones here.'' |
− | **Patients receiving enzyme-inducing antiepileptic drugs (EIAEDs) are treated with a higher dose: | + | |
− | *[[Bevacizumab (Avastin)]] 10 mg/kg IV once on day 1, given second, 90 minutes after the start of irinotecan | + | ====Chemotherapy==== |
+ | *[[Irinotecan (Camptosar)]] 125 mg/m<sup>2</sup> IV over 90 minutes once on day 1, '''given first''' | ||
+ | **Patients receiving enzyme-inducing antiepileptic drugs (EIAEDs) are treated with a higher dose: 340 mg/m<sup>2</sup> (Vredenburgh et al. 2007 & Norden et al. 2008) or 350 mg/m<sup>2</sup> (Chen et al. 2007) IV over 90 minutes once on day 1, '''given first''' | ||
+ | *[[Bevacizumab (Avastin)]] 10 mg/kg IV once on day 1, '''given second, 90 minutes after the start of irinotecan''' | ||
**Infusion times for bevacizumab are 90 minutes for the first dose, then if tolerated, 60 minutes for the second dose, and 30 minutes for the third dose and later | **Infusion times for bevacizumab are 90 minutes for the first dose, then if tolerated, 60 minutes for the second dose, and 30 minutes for the third dose and later | ||
− | + | ====Supportive medications==== | |
+ | *[[Steroid conversions|Steroids]] were generally maintained at the same dose | ||
− | + | '''14-day cycles, given until progression of disease or unacceptable toxicity''' | |
− | |||
− | ===Regimen #2 | + | ===Regimen #2 {{#subobject:7da12|Variant=1}}=== |
− | + | {| border="1" style="text-align:center;" !align="left" | |
− | <span | + | |'''Study''' |
− | style="background:# | + | |[[Levels_of_Evidence#Evidence|'''Evidence''']] |
+ | |- | ||
+ | |[http://jco.ascopubs.org/content/25/30/4722.long Vredenburgh et al. 2007] | ||
+ | |<span | ||
+ | style="background:#ff0000; | ||
padding:3px 6px 3px 6px; | padding:3px 6px 3px 6px; | ||
border-color:black; | border-color:black; | ||
border-width:2px; | border-width:2px; | ||
− | border-style:solid;">Phase II</span> | + | border-style:solid;">Phase II, <20 pts</span> |
+ | |- | ||
+ | |} | ||
+ | ====Chemotherapy==== | ||
+ | *[[Irinotecan (Camptosar)]] 125 mg/m<sup>2</sup> IV over 90 minutes once per day on days 1, 8, 22, 29, '''given first''' | ||
+ | **Patients receiving enzyme-inducing antiepileptic drugs (EIAEDs) are treated with a higher dose: 350 mg/m<sup>2</sup> IV over 90 minutes once per day on days 1, 8, 22, 29, '''given first''' | ||
+ | *[[Bevacizumab (Avastin)]] 15 mg/kg IV once per day on days 1 & 22, '''given second, 90 minutes after the start of irinotecan''' | ||
+ | **Infusion times for bevacizumab are 90 minutes for the first dose, then if tolerated, 60 minutes for the second dose, and 30 minutes for the third dose and later | ||
− | + | ====Supportive medications==== | |
− | * | + | *[[Steroid conversions|Steroids]] were generally maintained at the same dose |
− | |||
− | |||
'''42-day (6-week) cycles, given until progression of disease or unacceptable toxicity''' | '''42-day (6-week) cycles, given until progression of disease or unacceptable toxicity''' | ||
− | |||
− | |||
− | |||
===References=== | ===References=== | ||
Line 882: | Line 1,139: | ||
# Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007 Oct 20;25(30):4722-9. [http://jco.ascopubs.org/content/25/30/4722.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/17947719 PubMed] | # Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007 Oct 20;25(30):4722-9. [http://jco.ascopubs.org/content/25/30/4722.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/17947719 PubMed] | ||
# Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, Kesari S, Wen PY. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. 2008 Mar 4;70(10):779-87. [http://www.neurology.org/content/70/10/779.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/18316689 PubMed] | # Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, Kesari S, Wen PY. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. 2008 Mar 4;70(10):779-87. [http://www.neurology.org/content/70/10/779.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/18316689 PubMed] | ||
+ | <!-- Presented in part at the 12th Annual Meeting of the Society for Neuro-Oncology, November 15-18, 2007, Dallas, TX, and at the 44th Annual Meeting of the American Society of Clinical Oncology, May 30-June 3, 2008, Chicago, IL. --> | ||
# Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009 Oct 1;27(28):4733-40. Epub 2009 Aug 31. [http://jco.ascopubs.org/content/27/28/4733.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/19720927 PubMed] | # Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009 Oct 1;27(28):4733-40. Epub 2009 Aug 31. [http://jco.ascopubs.org/content/27/28/4733.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/19720927 PubMed] | ||
Line 890: | Line 1,148: | ||
|} | |} | ||
===Regimen {{#subobject:fc297c|Variant=1}}=== | ===Regimen {{#subobject:fc297c|Variant=1}}=== | ||
− | + | {| border="1" style="text-align:center;" !align="left" | |
− | <span | + | |'''Study''' |
+ | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
+ | |- | ||
+ | |[http://www.neurology.org/content/63/7/1281.long Brandes et al. 2004] | ||
+ | |<span | ||
style="background:#EEEE00; | style="background:#EEEE00; | ||
padding:3px 6px 3px 6px; | padding:3px 6px 3px 6px; | ||
Line 897: | Line 1,159: | ||
border-width:2px; | border-width:2px; | ||
border-style:solid;">Phase II</span> | border-style:solid;">Phase II</span> | ||
+ | |- | ||
+ | |} | ||
+ | ====Chemotherapy==== | ||
+ | *[[Carmustine (BiCNU)]] 80 mg/m<sup>2</sup> IV once per day on days 1 to 3 | ||
− | + | ====Supportive medications==== | |
− | |||
− | |||
− | |||
− | Supportive medications | ||
*[[Antiemesis]] prophylaxis with [[Ondansetron (Zofran)]] | *[[Antiemesis]] prophylaxis with [[Ondansetron (Zofran)]] | ||
*[[Steroid conversions|Steroids]] at lowest dose necessary | *[[Steroid conversions|Steroids]] at lowest dose necessary | ||
+ | |||
+ | '''8-week cycle for up to 6 cycles''' | ||
===References=== | ===References=== | ||
Line 915: | Line 1,179: | ||
|} | |} | ||
===Regimen {{#subobject:d0ffd5|Variant=1}}=== | ===Regimen {{#subobject:d0ffd5|Variant=1}}=== | ||
− | + | {| border="1" style="text-align:center;" !align="left" | |
− | <span | + | |'''Study''' |
+ | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
+ | |- | ||
+ | |[http://onlinelibrary.wiley.com/doi/10.1002/cncr.20072/full Chamberlain & Tsao-Wei, 2004] | ||
+ | |<span | ||
style="background:#EEEE00; | style="background:#EEEE00; | ||
padding:3px 6px 3px 6px; | padding:3px 6px 3px 6px; | ||
Line 922: | Line 1,190: | ||
border-width:2px; | border-width:2px; | ||
border-style:solid;">Phase II</span> | border-style:solid;">Phase II</span> | ||
+ | |- | ||
+ | |} | ||
+ | ====Chemotherapy==== | ||
+ | *[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1 & 2 | ||
− | + | ====Supportive medications==== | |
− | |||
− | |||
− | |||
− | Supportive medications | ||
*[[Dexamethasone (Decadron)]] allowed for control of neurologic symptoms | *[[Dexamethasone (Decadron)]] allowed for control of neurologic symptoms | ||
− | *Ondansetron (Zofran) 0.15 mg/kg IV once prior to cyclophosphamide | + | *[[Ondansetron (Zofran)]] 0.15 mg/kg IV once prior to cyclophosphamide |
*[[Dexamethasone (Decadron)]] 4 mg IV once prior to cyclophosphamide | *[[Dexamethasone (Decadron)]] 4 mg IV once prior to cyclophosphamide | ||
*1 liter normal saline IV over 2 hours prior to cyclophosphamide | *1 liter normal saline IV over 2 hours prior to cyclophosphamide | ||
− | *Prochlorperazine (Compazine) (dose/schedule not specified) prn nausea/vomiting | + | *[[Prochlorperazine (Compazine)]] (dose/schedule not specified) prn nausea/vomiting |
+ | |||
+ | '''28-day cycles''' | ||
===References=== | ===References=== | ||
Line 943: | Line 1,213: | ||
|} | |} | ||
− | ===Regimen | + | ===Regimen {{#subobject:1c1791|Variant=1}}=== |
− | + | {| border="1" style="text-align:center;" !align="left" | |
− | <span | + | |'''Study''' |
+ | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
+ | |- | ||
+ | |[http://annonc.oxfordjournals.org/content/16/10/1702.long Dresemann et al. 2005] | ||
+ | |<span | ||
style="background:#EEEE00; | style="background:#EEEE00; | ||
padding:3px 6px 3px 6px; | padding:3px 6px 3px 6px; | ||
Line 951: | Line 1,225: | ||
border-width:2px; | border-width:2px; | ||
border-style:solid;">Non-randomized</span> | border-style:solid;">Non-randomized</span> | ||
− | + | |- | |
− | + | |} | |
+ | ====Chemotherapy==== | ||
*[[Imatinib (Gleevec)]] 400 mg PO once per day | *[[Imatinib (Gleevec)]] 400 mg PO once per day | ||
*[[Hydroxyurea (Hydrea)]] 500 mg PO BID | *[[Hydroxyurea (Hydrea)]] 500 mg PO BID | ||
− | ''' | + | '''Given until progression of disease''' |
===References=== | ===References=== | ||
Line 967: | Line 1,242: | ||
|} | |} | ||
===Regimen {{#subobject:24c9e2|Variant=1}}=== | ===Regimen {{#subobject:24c9e2|Variant=1}}=== | ||
− | + | {| border="1" style="text-align:center;" !align="left" | |
− | <span | + | |'''Study''' |
+ | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
+ | |- | ||
+ | |[http://jco.ascopubs.org/content/17/5/1516.long Friedman et al. 1999] | ||
+ | |<span | ||
style="background:#EEEE00; | style="background:#EEEE00; | ||
padding:3px 6px 3px 6px; | padding:3px 6px 3px 6px; | ||
Line 974: | Line 1,253: | ||
border-width:2px; | border-width:2px; | ||
border-style:solid;">Phase II</span> | border-style:solid;">Phase II</span> | ||
+ | |- | ||
+ | |} | ||
+ | ====Chemotherapy==== | ||
+ | *[[Irinotecan (Camptosar)]] 125 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22 | ||
+ | **If tolerated, dose could be increased to 150 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22 | ||
− | *[[ | + | ====Supportive medications==== |
− | * | + | *[[Steroid conversions|Steroids]] at lowest dose necessary |
+ | *Avoid laxatives and magnesium-containing antacids due to potential for diarrhea | ||
'''42-day (6-week) cycles, given until progression of disease or unacceptable toxicity''' | '''42-day (6-week) cycles, given until progression of disease or unacceptable toxicity''' | ||
− | |||
− | |||
− | |||
− | |||
===References=== | ===References=== | ||
Line 1,008: | Line 1,289: | ||
|- | |- | ||
|} | |} | ||
+ | ====Chemotherapy==== | ||
+ | *[[Lomustine (Ceenu)]] 100 to 130 mg/m<sup>2</sup> PO once on day 1 | ||
− | + | ====Supportive medications==== | |
− | |||
− | Supportive medications | ||
*Enzyme-inducing antiepileptic drugs (EIAEDs) needed to be discontinued 14 days before enrolling in the trial | *Enzyme-inducing antiepileptic drugs (EIAEDs) needed to be discontinued 14 days before enrolling in the trial | ||
Line 1,019: | Line 1,300: | ||
# Wick W, Puduvalli VK, Chamberlain MC, van den Bent MJ, Carpentier AF, Cher LM, Mason W, Weller M, Hong S, Musib L, Liepa AM, Thornton DE, Fine HA. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol. 2010 Mar 1;28(7):1168-74. Epub 2010 Feb 1. [http://jco.ascopubs.org/content/28/7/1168.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/20124186 PubMed] | # Wick W, Puduvalli VK, Chamberlain MC, van den Bent MJ, Carpentier AF, Cher LM, Mason W, Weller M, Hong S, Musib L, Liepa AM, Thornton DE, Fine HA. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol. 2010 Mar 1;28(7):1168-74. Epub 2010 Feb 1. [http://jco.ascopubs.org/content/28/7/1168.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/20124186 PubMed] | ||
− | ==PCV | + | ==PCV== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
|[[#toc|back to top]] | |[[#toc|back to top]] | ||
|} | |} | ||
− | PCV: '''<u>P</u>'''rocarbazine, '''<u>C</u>'''CNU, '''<u>V</u>'''incristine | + | PCV: '''<u>P</u>'''rocarbazine, '''<u>C</u>'''CNU (Lomustine), '''<u>V</u>'''incristine |
+ | |||
+ | ===Regimen #1 {{#subobject:c3f4c2|Variant=1}}=== | ||
+ | {| border="1" style="text-align:center;" !align="left" | ||
+ | |'''Study''' | ||
+ | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
+ | |- | ||
+ | |[http://www.ncbi.nlm.nih.gov/pubmed/7407756 Levin et al. 1980] | ||
+ | |<span | ||
+ | style="background:#EEEE00; | ||
+ | padding:3px 6px 3px 6px; | ||
+ | border-color:black; | ||
+ | border-width:2px; | ||
+ | border-style:solid;">Non-randomized</span> | ||
+ | |- | ||
+ | |} | ||
+ | ====Chemotherapy==== | ||
+ | *[[Procarbazine (Matulane)]] 60 mg/m<sup>2</sup> PO once per day on days 8 to 21 | ||
+ | *[[Lomustine (Ceenu)]] 110 mg/m<sup>2</sup> PO once on day 1 | ||
+ | *[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once per day on days 8 & 29 | ||
+ | |||
+ | '''6-week cycles, given until progression of disease or unacceptable toxicity''' | ||
+ | |||
+ | ===Regimen #2, higher doses {{#subobject:aba32b|Variant=1}}=== | ||
+ | {| border="1" style="text-align:center;" !align="left" | ||
+ | |'''Study''' | ||
+ | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
+ | |- | ||
+ | |[http://jco.ascopubs.org/content/12/10/2013.long Cairncross et al. 1994] | ||
+ | |<span | ||
+ | style="background:#EEEE00; | ||
+ | padding:3px 6px 3px 6px; | ||
+ | border-color:black; | ||
+ | border-width:2px; | ||
+ | border-style:solid;">Phase II</span> | ||
+ | |- | ||
+ | |} | ||
+ | ====Chemotherapy==== | ||
+ | *[[Procarbazine (Matulane)]] 75 mg/m<sup>2</sup> PO once per day on days 8 to 21 | ||
+ | *[[Lomustine (Ceenu)]] 130 mg/m<sup>2</sup> PO once on day 1 | ||
+ | *[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (dose not capped) IV once per day on days 8 & 29 | ||
+ | |||
+ | '''6-week cycles, given until progression of disease or unacceptable toxicity''' | ||
− | + | ===References=== | |
+ | # Levin VA, Edwards MS, Wright DC, Seager ML, Schimberg TP, Townsend JJ, Wilson CB. Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors. Cancer Treat Rep. 1980 Feb-Mar;64(2-3):237-44. '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/7407756 PubMed] | ||
+ | # Cairncross G, Macdonald D, Ludwin S, Lee D, Cascino T, Buckner J, Fulton D, Dropcho E, Stewart D, Schold C Jr et al. Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1994 Oct;12(10):2013-21. [http://jco.ascopubs.org/content/12/10/2013.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/7931469 PubMed] | ||
==Procarbazine (Matulane) {{#subobject:69a372|Regimen=1}}== | ==Procarbazine (Matulane) {{#subobject:69a372|Regimen=1}}== | ||
Line 1,034: | Line 1,359: | ||
|} | |} | ||
===Regimen {{#subobject:d1a052|Variant=1}}=== | ===Regimen {{#subobject:d1a052|Variant=1}}=== | ||
− | + | {| border="1" style="text-align:center;" !align="left" | |
− | <span | + | |'''Study''' |
+ | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
+ | |- | ||
+ | |[http://www.nature.com/bjc/journal/v83/n5/full/6691316a.html Yung et al. 2000] | ||
+ | |<span | ||
style="background:#EEEE00; | style="background:#EEEE00; | ||
padding:3px 6px 3px 6px; | padding:3px 6px 3px 6px; | ||
Line 1,041: | Line 1,370: | ||
border-width:2px; | border-width:2px; | ||
border-style:solid;">Phase II</span> | border-style:solid;">Phase II</span> | ||
+ | |- | ||
+ | |} | ||
− | *Patients who had never previously received chemotherapy: | + | ====Chemotherapy==== |
− | *Patients who previously received chemotherapy started with | + | *[[Procarbazine (Matulane)]] as follows: |
+ | **Patients who had never previously received chemotherapy: 150 mg/m<sup>2</sup> PO once per day on days 1 to 28 | ||
+ | **Patients who previously received chemotherapy started with 125 mg/m<sup>2</sup> PO once per day on days 1 to 28 | ||
− | + | ====Supportive medications==== | |
+ | *[[Steroid conversions|Steroids]] at lowest dose necessary | ||
− | + | '''8-week cycle for up to 2 years, progression of disease, or unacceptable toxicity''' | |
− | |||
===References=== | ===References=== | ||
Line 1,058: | Line 1,391: | ||
|[[#toc|back to top]] | |[[#toc|back to top]] | ||
|} | |} | ||
− | ===Regimen #1, | + | ===Regimen #1, continuous therapy {{#subobject:f18af9|Variant=1}}=== |
− | + | {| border="1" style="text-align:center;" !align="left" | |
− | <span | + | |'''Study''' |
+ | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
+ | |- | ||
+ | |[http://onlinelibrary.wiley.com/doi/10.1002/cncr.23813/full Perry et al. 2008 (RESCUE)] | ||
+ | |<span | ||
style="background:#EEEE00; | style="background:#EEEE00; | ||
padding:3px 6px 3px 6px; | padding:3px 6px 3px 6px; | ||
Line 1,066: | Line 1,403: | ||
border-width:2px; | border-width:2px; | ||
border-style:solid;">Phase II</span> | border-style:solid;">Phase II</span> | ||
− | + | |- | |
+ | |} | ||
+ | ====Chemotherapy==== | ||
Patients who have first recurrence after surgery and conventional external beam radiation: | Patients who have first recurrence after surgery and conventional external beam radiation: | ||
− | *[[Temozolomide (Temodar)]] 150 to 200 mg/ | + | *[[Temozolomide (Temodar)]] 150 to 200 mg/m<sup>2</sup> PO once per day on days 1 to 5 |
'''28-day cycles''' | '''28-day cycles''' | ||
Patients with progressive disease are changed to: | Patients with progressive disease are changed to: | ||
− | *[[Temozolomide (Temodar)]] 50 mg/ | + | *[[Temozolomide (Temodar)]] 50 mg/m<sup>2</sup> PO once per day, taken continuously without treatment break |
− | ''' | + | '''Given until progression of disease or unacceptable toxicity''' |
Patients who had recurrent/progressive disease after surgery and concurrent radiation and temozolomide are treated with: | Patients who had recurrent/progressive disease after surgery and concurrent radiation and temozolomide are treated with: | ||
− | *[[Temozolomide (Temodar)]] 50 mg/ | + | *[[Temozolomide (Temodar)]] 50 mg/m<sup>2</sup> PO once per day, taken continuously without treatment break |
− | ''' | + | '''Given until progression of disease or unacceptable toxicity''' |
+ | |||
+ | ===Regimen #2, traditional dosing {{#subobject:f06af9|Variant=1}}=== | ||
+ | {| border="1" style="text-align:center;" !align="left" | ||
+ | |'''Study''' | ||
+ | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
+ | |- | ||
+ | |[http://onlinelibrary.wiley.com/doi/10.1002/cncr.22961/full Nicholson et al. 2007] | ||
+ | |<span | ||
+ | style="background:#EEEE00; | ||
+ | padding:3px 6px 3px 6px; | ||
+ | border-color:black; | ||
+ | border-width:2px; | ||
+ | border-style:solid;">Non-randomized</span> | ||
+ | |- | ||
+ | |} | ||
+ | ====Chemotherapy==== | ||
+ | *[[Temozolomide (Temodar)]] 200 mg/m<sup>2</sup> PO once per day on days 1 to 5 | ||
+ | **Patients who previously received craniospinal irradiation (CSI) instead received 180 mg/m<sup>2</sup> PO once per day on days 1 to 5 | ||
− | + | '''28-day cycle for up to 11 cycles''' | |
− | |||
− | ===Regimen #3 | + | ===Regimen #3 {{#subobject:4cde86|Variant=1}}=== |
− | + | {| border="1" style="text-align:center;" !align="left" | |
− | <span | + | |'''Study''' |
+ | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
+ | |- | ||
+ | |[http://www.nature.com/bjc/journal/v83/n5/full/6691316a.html Yung et al. 2000] | ||
+ | |<span | ||
style="background:#EEEE00; | style="background:#EEEE00; | ||
padding:3px 6px 3px 6px; | padding:3px 6px 3px 6px; | ||
Line 1,093: | Line 1,453: | ||
border-width:2px; | border-width:2px; | ||
border-style:solid;">Phase II</span> | border-style:solid;">Phase II</span> | ||
+ | |- | ||
+ | |} | ||
− | *Patients who had never previously received chemotherapy: | + | ====Chemotherapy==== |
− | *Patients who previously received chemotherapy started with | + | *[[Temozolomide (Temodar)]] as follows: |
+ | **Patients who had never previously received chemotherapy: 200 mg/m<sup>2</sup> PO once per day on days 1 to 5 | ||
+ | **Patients who previously received chemotherapy started with 150 mg/m<sup>2</sup> PO once per day on days 1 to 5 | ||
− | '''28-day | + | '''28-day cycle for up to 2 years, until progression of disease, or unacceptable toxicity''' |
===References=== | ===References=== | ||
# Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Vick NA, Rampling R, Friedman H, Phillips P, Bruner J, Yue N, Osoba D, Zaknoen S, Levin VA. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 2000 Sep;83(5):588-93. [http://www.nature.com/bjc/journal/v83/n5/full/6691316a.html link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/10944597 PubMed] | # Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Vick NA, Rampling R, Friedman H, Phillips P, Bruner J, Yue N, Osoba D, Zaknoen S, Levin VA. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 2000 Sep;83(5):588-93. [http://www.nature.com/bjc/journal/v83/n5/full/6691316a.html link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/10944597 PubMed] | ||
+ | # Nicholson HS, Kretschmar CS, Krailo M, Bernstein M, Kadota R, Fort D, Friedman H, Harris MB, Tedeschi-Blok N, Mazewski C, Sato J, Reaman GH. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer. 2007 Oct 1;110(7):1542-50. [http://onlinelibrary.wiley.com/doi/10.1002/cncr.22961/full link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/17705175 PubMed] | ||
# Perry JR, Rizek P, Cashman R, Morrison M, Morrison T. Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach. Cancer. 2008 Oct 15;113(8):2152-7. [http://onlinelibrary.wiley.com/doi/10.1002/cncr.23813/full link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/18756530 PubMed] | # Perry JR, Rizek P, Cashman R, Morrison M, Morrison T. Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach. Cancer. 2008 Oct 15;113(8):2152-7. [http://onlinelibrary.wiley.com/doi/10.1002/cncr.23813/full link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/18756530 PubMed] | ||
− | # Perry JR, Bélanger K, Mason WP, Fulton D, Kavan P, Easaw J, Shields C, Kirby S, Macdonald DR, Eisenstat DD, Thiessen B, Forsyth P, Pouliot JF. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol. 2010 Apr 20;28(12):2051-7. Epub 2010 Mar 22. [http://jco.ascopubs.org/content/28/12/2051.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/20308655 PubMed] | + | ## '''Update:''' Perry JR, Bélanger K, Mason WP, Fulton D, Kavan P, Easaw J, Shields C, Kirby S, Macdonald DR, Eisenstat DD, Thiessen B, Forsyth P, Pouliot JF. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol. 2010 Apr 20;28(12):2051-7. Epub 2010 Mar 22. [http://jco.ascopubs.org/content/28/12/2051.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/20308655 PubMed] |
=Supratentorial astrocytoma or oligodendroglioma chemoradiation & adjuvant therapy= | =Supratentorial astrocytoma or oligodendroglioma chemoradiation & adjuvant therapy= | ||
Line 1,111: | Line 1,476: | ||
|} | |} | ||
===Regimen {{#subobject:2344c2|Variant=1}}=== | ===Regimen {{#subobject:2344c2|Variant=1}}=== | ||
− | ''Note: The patients in the reference were treated for glioblastoma, but the NCCN, Central Nervous System Cancers version 1.2013 lists this as an acceptable regimen for supratentorial astrocytoma or oligodendroglioma. | + | ''Note: The patients in the reference were treated for glioblastoma, but the NCCN, Central Nervous System Cancers version 1.2013 lists this as an acceptable regimen for supratentorial astrocytoma or oligodendroglioma. No primary reference could be found for this regimen in this disease.'' |
+ | ====Chemoradiotherapy==== | ||
*Concurrent radiation therapy, 2 Gy fractions x 30 fractions given 5 days per week, for a total dose of 60 Gy | *Concurrent radiation therapy, 2 Gy fractions x 30 fractions given 5 days per week, for a total dose of 60 Gy | ||
− | *[[Temozolomide (Temodar)]] 75 mg/ | + | *[[Temozolomide (Temodar)]] 75 mg/m<sup>2</sup> PO once per day, used starting the first day of radiation therapy until the last day of radiation therapy, and no longer than 49 days |
4 weeks after completion of radiation therapy, patients received additional adjuvant therapy: | 4 weeks after completion of radiation therapy, patients received additional adjuvant therapy: | ||
− | *[[Temozolomide (Temodar)]] 150 mg/ | + | *[[Temozolomide (Temodar)]] 150 mg/m<sup>2</sup> PO once per day on days 1 to 5 of cycle 1; if tolerated, in cycles 2 and on, the dose is increased to [[Temozolomide (Temodar)]] 200 mg/m<sup>2</sup> PO once per day on days 1 to 5 |
− | + | ====Supportive medications==== | |
− | |||
− | Supportive medications | ||
*PCP prophylaxis during radiation therapy & temozolomide with one of the following: | *PCP prophylaxis during radiation therapy & temozolomide with one of the following: | ||
**[[Trimethoprim/Sulfamethoxazole (Bactrim DS)|Trimethoprim/Sulfamethoxazole (Bactrim)]] | **[[Trimethoprim/Sulfamethoxazole (Bactrim DS)|Trimethoprim/Sulfamethoxazole (Bactrim)]] | ||
− | **Pentamidine (Nebupent) 300 mg nebulized inhaled | + | **[[Pentamidine (Nebupent)]] 300 mg nebulized inhaled |
− | *Metoclopramide (Reglan) or [[Antiemesis|5-HT3 antagonist]] required during the adjuvant temozolomide-only period; their use was also recommended before the initial doses of radiation therapy & temozolomide | + | *[[Metoclopramide (Reglan)]] or [[Antiemesis|5-HT3 antagonist]] required during the adjuvant temozolomide-only period; their use was also recommended before the initial doses of radiation therapy & temozolomide |
+ | |||
+ | '''28-day cycle for 6 cycles''' | ||
===References=== | ===References=== | ||
Line 1,136: | Line 1,502: | ||
|} | |} | ||
===Regimen {{#subobject:24c607|Variant=1}}=== | ===Regimen {{#subobject:24c607|Variant=1}}=== | ||
− | + | {| border="1" style="text-align:center;" !align="left" | |
− | <span | + | |'''Study''' |
+ | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
+ | |- | ||
+ | |[http://thejns.org/doi/pdf/10.3171/foc.1998.4.4.6 Moghrabi et al. 1998] | ||
+ | |<span | ||
style="background:#EEEE00; | style="background:#EEEE00; | ||
padding:3px 6px 3px 6px; | padding:3px 6px 3px 6px; | ||
Line 1,143: | Line 1,513: | ||
border-width:2px; | border-width:2px; | ||
border-style:solid;">Phase II</span> | border-style:solid;">Phase II</span> | ||
− | + | |- | |
− | *[[Carboplatin (Paraplatin)]] 560 mg/ | + | |} |
+ | ====Chemotherapy==== | ||
+ | *[[Carboplatin (Paraplatin)]] 560 mg/m<sup>2</sup> IV over 1 hour once on day 1 | ||
**Mixed in D5 1/2 NS | **Mixed in D5 1/2 NS | ||
− | + | ====Supportive medications==== | |
+ | *Hydration for 1 hour before chemotherapy, and for 1 hour after chemotherapy; total volume including carboplatin is 900 mL/m<sup>2</sup> | ||
− | + | '''28-day cycle for up to 12 cycles beyond the maximum response, given until progression of disease, or unacceptable toxicity''' | |
− | |||
===References=== | ===References=== | ||
Line 1,161: | Line 1,533: | ||
|} | |} | ||
===Regimen {{#subobject:531596|Variant=1}}=== | ===Regimen {{#subobject:531596|Variant=1}}=== | ||
− | + | {| border="1" style="text-align:center;" !align="left" | |
− | <span | + | |'''Study''' |
+ | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
+ | |- | ||
+ | |[http://annonc.oxfordjournals.org/content/14/12/1727.long Brandes et al. 2003] | ||
+ | |<span | ||
style="background:#EEEE00; | style="background:#EEEE00; | ||
padding:3px 6px 3px 6px; | padding:3px 6px 3px 6px; | ||
Line 1,168: | Line 1,544: | ||
border-width:2px; | border-width:2px; | ||
border-style:solid;">Phase II</span> | border-style:solid;">Phase II</span> | ||
+ | |- | ||
+ | |} | ||
+ | ====Chemotherapy==== | ||
+ | *[[Carboplatin (Paraplatin)]] 350 mg/m<sup>2</sup> IV once on day 1 | ||
+ | *[[Teniposide (Vumon)]] 50 mg/m<sup>2</sup> IV once per day on days 1 to 3 | ||
− | + | ====Supportive medications==== | |
− | |||
− | |||
− | |||
− | |||
− | Supportive medications | ||
*Prophylactic [[antiemesis|5-HT3 antagonists]] routinely used | *Prophylactic [[antiemesis|5-HT3 antagonists]] routinely used | ||
*Lowest dose of [[Steroid conversions|corticosteroids]] necessary to maintain neurologic stability | *Lowest dose of [[Steroid conversions|corticosteroids]] necessary to maintain neurologic stability | ||
*Antiepileptic medications for all patients | *Antiepileptic medications for all patients | ||
+ | |||
+ | '''28-day cycle for up to 10 cycles''' | ||
===References=== | ===References=== | ||
Line 1,188: | Line 1,566: | ||
|} | |} | ||
===Regimen {{#subobject:55de5f|Variant=1}}=== | ===Regimen {{#subobject:55de5f|Variant=1}}=== | ||
− | + | {| border="1" style="text-align:center;" !align="left" | |
− | <span | + | |'''Study''' |
+ | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
+ | |- | ||
+ | |[http://www.springerlink.com/content/c34647v88t66m727/ Massimino et al. 2010] | ||
+ | |<span | ||
style="background:#EEEE00; | style="background:#EEEE00; | ||
padding:3px 6px 3px 6px; | padding:3px 6px 3px 6px; | ||
Line 1,195: | Line 1,577: | ||
border-width:2px; | border-width:2px; | ||
border-style:solid;">Non-randomized</span> | border-style:solid;">Non-randomized</span> | ||
+ | |- | ||
+ | |} | ||
+ | ''Note: In children <1 year old or <10 kg, "doses were adjusted to their weight"--reference does not say exactly how doses are adjusted.'' | ||
+ | ====Chemotherapy==== | ||
+ | *[[Cisplatin (Platinol)]] 25 mg/m<sup>2</sup> IV over 2 hours once per day on days 1 to 3, '''given first''' | ||
+ | *[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1 to 3, '''given second''' | ||
− | * | + | ====Supportive medications==== |
− | + | *Hydration for 2 hours before chemotherapy, and for 2 hours after chemotherapy | |
− | |||
− | |||
− | |||
− | + | '''28-day cycle for 4 cycles, then 35-day cycle for 3 cycles, then 42-day cycle for 3 cycles''' | |
− | |||
===References=== | ===References=== | ||
Line 1,213: | Line 1,597: | ||
|[[#toc|back to top]] | |[[#toc|back to top]] | ||
|} | |} | ||
− | PCV: '''<u>P</u>'''rocarbazine, '''<u>C</u>'''CNU, '''<u>V</u>'''incristine | + | PCV: '''<u>P</u>'''rocarbazine, '''<u>C</u>'''CNU (Lomustine), '''<u>V</u>'''incristine |
− | ===Regimen | + | ===Regimen {{#subobject:6c3103|Variant=1}}=== |
− | + | {| border="1" style="text-align:center;" !align="left" | |
− | <span | + | |'''Study''' |
+ | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
+ | |- | ||
+ | |[http://onlinelibrary.wiley.com/doi/10.1002/cncr.20611/full Brandes et al. 2004] | ||
+ | |<span | ||
style="background:#EEEE00; | style="background:#EEEE00; | ||
padding:3px 6px 3px 6px; | padding:3px 6px 3px 6px; | ||
Line 1,223: | Line 1,611: | ||
border-width:2px; | border-width:2px; | ||
border-style:solid;">Phase II</span> | border-style:solid;">Phase II</span> | ||
+ | |- | ||
+ | |} | ||
+ | ====Chemotherapy==== | ||
+ | *[[Procarbazine (Matulane)]] 60 mg/m<sup>2</sup> PO once per day on days 8 to 21 | ||
+ | *[[Lomustine (Ceenu)]] 110 mg/m<sup>2</sup> PO once on day 1 | ||
+ | *[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once per day on days 8 & 29 | ||
− | + | ====Supportive medications==== | |
− | |||
− | |||
− | |||
− | |||
− | |||
− | Supportive medications | ||
*Routine use of prophylactic [[antiemesis|5-HT3 antagonists]] | *Routine use of prophylactic [[antiemesis|5-HT3 antagonists]] | ||
*[[Steroid conversions|Steroids]] given at the lowest dose required by patient's neurologic status | *[[Steroid conversions|Steroids]] given at the lowest dose required by patient's neurologic status | ||
+ | |||
+ | '''6-week cycle for up to 6 cycles''' | ||
===References=== | ===References=== | ||
Line 1,243: | Line 1,633: | ||
|[[#toc|back to top]] | |[[#toc|back to top]] | ||
|} | |} | ||
− | ===Regimen #1, | + | ===Regimen #1, low dose {{#subobject:863ec|Variant=1}}=== |
− | + | {| border="1" style="text-align:center;" !align="left" | |
− | <span | + | |'''Study''' |
+ | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
+ | |- | ||
+ | |[http://www.springerlink.com/content/2015983316050j22/ Pouratian et al. 2006] | ||
+ | |<span | ||
style="background:#ff0000; | style="background:#ff0000; | ||
padding:3px 6px 3px 6px; | padding:3px 6px 3px 6px; | ||
Line 1,251: | Line 1,645: | ||
border-width:2px; | border-width:2px; | ||
border-style:solid;">Retrospective</span> | border-style:solid;">Retrospective</span> | ||
+ | |- | ||
+ | |} | ||
+ | ====Chemotherapy==== | ||
+ | *[[Temozolomide (Temodar)]] 75 mg/m<sup>2</sup> PO once per day on days 1 to 21 | ||
− | + | ====Supportive medications==== | |
− | |||
− | |||
− | |||
− | Supportive medications | ||
*PCP prophylaxis with [[Trimethoprim/Sulfamethoxazole (Bactrim DS)|Trimethoprim/Sulfamethoxazole (Bactrim)]] | *PCP prophylaxis with [[Trimethoprim/Sulfamethoxazole (Bactrim DS)|Trimethoprim/Sulfamethoxazole (Bactrim)]] | ||
*[[Antiemesis|Antiemetics]] and stool softeners used as needed | *[[Antiemesis|Antiemetics]] and stool softeners used as needed | ||
− | ===Regimen #2, | + | '''28-day cycle for 12 to 15 cycles''' |
− | + | ||
− | <span | + | ===Regimen #2, low dose, longer cycles {{#subobject:50fd6b|Variant=1}}=== |
+ | {| border="1" style="text-align:center;" !align="left" | ||
+ | |'''Study''' | ||
+ | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
+ | |- | ||
+ | |[http://clincancerres.aacrjournals.org/content/15/1/330.long Kesari et al. 2009] | ||
+ | |<span | ||
style="background:#EEEE00; | style="background:#EEEE00; | ||
padding:3px 6px 3px 6px; | padding:3px 6px 3px 6px; | ||
Line 1,268: | Line 1,668: | ||
border-width:2px; | border-width:2px; | ||
border-style:solid;">Phase II</span> | border-style:solid;">Phase II</span> | ||
+ | |- | ||
+ | |} | ||
+ | ====Chemotherapy==== | ||
+ | *[[Temozolomide (Temodar)]] 75 mg/m<sup>2</sup> PO once per day on days 1 to 49 | ||
− | *[[ | + | ====Supportive medications==== |
+ | *PCP prophylaxis with [[Trimethoprim/Sulfamethoxazole (Bactrim DS)|Trimethoprim/Sulfamethoxazole (Bactrim)]] | ||
− | '''77-day | + | '''77-day cycle for up to 6 cycles, progression of disease, or unacceptable toxicity''' |
− | + | ===Regimen #3, traditional initial dosing, then continuous therapy {{#subobject:3871fe|Variant=1}}=== | |
− | + | {| border="1" style="text-align:center;" !align="left" | |
− | + | |'''Study''' | |
− | ===Regimen #3, | + | |[[Levels_of_Evidence#Evidence|'''Evidence''']] |
− | + | |- | |
− | <span | + | |[http://onlinelibrary.wiley.com/doi/10.1002/cncr.23813/full Perry et al. 2008 (RESCUE)] |
− | style="background:# | + | |<span |
+ | style="background:#eeee00; | ||
padding:3px 6px 3px 6px; | padding:3px 6px 3px 6px; | ||
border-color:black; | border-color:black; | ||
border-width:2px; | border-width:2px; | ||
− | border-style:solid;"> | + | border-style:solid;">Phase II</span> |
− | + | |- | |
− | At first recurrence/progression: | + | |} |
− | *[[Temozolomide (Temodar)]] 150 to 200 mg/ | + | ''At first recurrence/progression:'' |
+ | ====Chemotherapy==== | ||
+ | *[[Temozolomide (Temodar)]] 150 to 200 mg/m<sup>2</sup> PO once per day on days 1 to 5 | ||
'''28-day cycles''' | '''28-day cycles''' | ||
− | Patients with progressive disease are changed to: | + | ''Patients with progressive disease are changed to:'' |
− | *[[Temozolomide (Temodar)]] 50 mg/ | + | *[[Temozolomide (Temodar)]] 50 mg/m<sup>2</sup> PO once per day, taken continuously without treatment break |
− | ''' | + | '''Given until progression of disease or unacceptable toxicity''' |
− | ===Regimen #4, | + | ===Regimen #4, traditional dosing {{#subobject:4fe632|Variant=1}}=== |
− | + | {| border="1" style="text-align:center;" !align="left" | |
− | <span | + | |'''Study''' |
+ | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
+ | |- | ||
+ | |[http://jco.ascopubs.org/content/19/9/2449.long Chinot et al. 2001] | ||
+ | |<span | ||
+ | style="background:#EEEE00; | ||
+ | padding:3px 6px 3px 6px; | ||
+ | border-color:black; | ||
+ | border-width:2px; | ||
+ | border-style:solid;">Phase II</span> | ||
+ | |- | ||
+ | |[http://onlinelibrary.wiley.com/doi/10.1002/cncr.22961/full Nicholson et al. 2007] | ||
+ | |<span | ||
style="background:#EEEE00; | style="background:#EEEE00; | ||
padding:3px 6px 3px 6px; | padding:3px 6px 3px 6px; | ||
Line 1,303: | Line 1,723: | ||
border-width:2px; | border-width:2px; | ||
border-style:solid;">Non-randomized</span> | border-style:solid;">Non-randomized</span> | ||
+ | |- | ||
+ | |} | ||
+ | ====Chemotherapy==== | ||
+ | *[[Temozolomide (Temodar)]] 200 mg/m<sup>2</sup> PO once per day on days 1 to 5 | ||
+ | **In Nicholson et al. 2007, patients who previously received craniospinal irradiation (CSI) instead received 180 mg/m<sup>2</sup> PO once per day on days 1 to 5 | ||
− | + | '''28-day cycle for up to 24 months (in Chinot et al. 2001) or 11 cycles (in Nicholson et al. 2007)''' | |
− | |||
− | |||
− | '''28-day | ||
===References=== | ===References=== | ||
Line 1,314: | Line 1,736: | ||
# Nicholson HS, Kretschmar CS, Krailo M, Bernstein M, Kadota R, Fort D, Friedman H, Harris MB, Tedeschi-Blok N, Mazewski C, Sato J, Reaman GH. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer. 2007 Oct 1;110(7):1542-50. [http://onlinelibrary.wiley.com/doi/10.1002/cncr.22961/full link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/17705175 PubMed] | # Nicholson HS, Kretschmar CS, Krailo M, Bernstein M, Kadota R, Fort D, Friedman H, Harris MB, Tedeschi-Blok N, Mazewski C, Sato J, Reaman GH. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer. 2007 Oct 1;110(7):1542-50. [http://onlinelibrary.wiley.com/doi/10.1002/cncr.22961/full link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/17705175 PubMed] | ||
# Perry JR, Rizek P, Cashman R, Morrison M, Morrison T. Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach. Cancer. 2008 Oct 15;113(8):2152-7. [http://onlinelibrary.wiley.com/doi/10.1002/cncr.23813/full link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/18756530 PubMed] | # Perry JR, Rizek P, Cashman R, Morrison M, Morrison T. Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach. Cancer. 2008 Oct 15;113(8):2152-7. [http://onlinelibrary.wiley.com/doi/10.1002/cncr.23813/full link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/18756530 PubMed] | ||
+ | ## '''Update:''' Perry JR, Bélanger K, Mason WP, Fulton D, Kavan P, Easaw J, Shields C, Kirby S, Macdonald DR, Eisenstat DD, Thiessen B, Forsyth P, Pouliot JF. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol. 2010 Apr 20;28(12):2051-7. Epub 2010 Mar 22. [http://jco.ascopubs.org/content/28/12/2051.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/20308655 PubMed] | ||
# Kesari S, Schiff D, Drappatz J, LaFrankie D, Doherty L, Macklin EA, Muzikansky A, Santagata S, Ligon KL, Norden AD, Ciampa A, Bradshaw J, Levy B, Radakovic G, Ramakrishna N, Black PM, Wen PY. Phase II study of protracted daily temozolomide for low-grade gliomas in adults. Clin Cancer Res. 2009 Jan 1;15(1):330-7. [http://clincancerres.aacrjournals.org/content/15/1/330.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/19118062 PubMed] | # Kesari S, Schiff D, Drappatz J, LaFrankie D, Doherty L, Macklin EA, Muzikansky A, Santagata S, Ligon KL, Norden AD, Ciampa A, Bradshaw J, Levy B, Radakovic G, Ramakrishna N, Black PM, Wen PY. Phase II study of protracted daily temozolomide for low-grade gliomas in adults. Clin Cancer Res. 2009 Jan 1;15(1):330-7. [http://clincancerres.aacrjournals.org/content/15/1/330.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/19118062 PubMed] | ||
+ | |||
+ | [[Category:Chemotherapy regimens]] | ||
+ | [[Category:Central nervous system (CNS) regimens]] |
Revision as of 01:05, 30 August 2016
Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.
18 regimens on this page
36 variants on this page
|
Anaplastic glioma - adjuvant therapy
PCV
back to top |
PCV: Procarbazine, CCNU, Vincristine
Regimen
Study | Evidence | Comparator |
Wick et al. 2009 (NOA-04) | Phase III | Radiation therapy Temozolomide |
Chemotherapy
- Procarbazine (Matulane) 60 mg/m2 PO once per day on days 8 to 21
- Lomustine (Ceenu) 110 mg/m2 PO once on day 1
- Vincristine (Oncovin) 2 mg IV once per day on days 8 & 29
8-week cycle for 4 cycles
Patients with stable disease or better received 2 more cycles of PCV. At time of disease progression patients proceeded to receive radiation therapy.
References
- Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, Sabel MC, Koeppen S, Ketter R, Meyermann R, Rapp M, Meisner C, Kortmann RD, Pietsch T, Wiestler OD, Ernemann U, Bamberg M, Reifenberger G, von Deimling A, Weller M. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol. 2009 Dec 10;27(35):5874-80. Epub 2009 Nov 9. link to original article contains verified protocol PubMed
Radiation therapy
back to top |
Regimen
Study | Evidence | Comparator |
MRC Brain Tumor Working Party 2001 | Phase III | RT -> PCV |
van den Bent et al. 2006 (EORTC 26951) | Phase III | RT -> PCV |
Wick et al. 2009 (NOA-04) | Phase III | PCV Temozolomide |
Adjuvant radiation alone; used as a comparator arm in the referenced trials.
Radiotherapy
- Radiation therapy with 1.8 to 2 Gy fractions given over 6 weeks for a total dose of 60 Gy
Patients on the NOA-04 trial were randomized to PCV versus temozolomide at the time of progression.
References
- Medical Research Council Brain Tumor Working Party. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. J Clin Oncol. 2001 Jan 15;19(2):509-18. link to original article contains verified protocol PubMed
- van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Haaxma-Reiche H, Kros JM, van Kouwenhoven MC, Vecht CJ, Allgeier A, Lacombe D, Gorlia T. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol. 2006 Jun 20;24(18):2715-22. link to original article contains verified protocol PubMed
- Update: van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre JY, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Enting RH, French PJ, Dinjens WN, Vecht CJ, Allgeier A, Lacombe D, Gorlia T, Hoang-Xuan K. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol. 2013 Jan 20;31(3):344-50. Epub 2012 Oct 15. link to original article PubMed
- Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, Sabel MC, Koeppen S, Ketter R, Meyermann R, Rapp M, Meisner C, Kortmann RD, Pietsch T, Wiestler OD, Ernemann U, Bamberg M, Reifenberger G, von Deimling A, Weller M. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol. 2009 Dec 10;27(35):5874-80. Epub 2009 Nov 9. link to original article contains verified protocol PubMed
Radiation & Carmustine (BiCNU)
back to top |
Regimen
Study | Evidence | Comparator |
Shapiro et al. 1989 (BTCG 8001) | Phase III | Carmustine/Procarbazine & RT Carmustine & Hydrea/Procarbazine & VM-26 & RT |
Radiotherapy
- Radiation therapy starting within 3 weeks after surgical resection, with one of the following:
- Whole brain: 172 cGy (rads) fractions x 35 fractions, given over 7 weeks for a total dose of 6020 cGy (6020 rads/~1700 rets)
- Whole brain & cone down: 172 cGy (rads) fractions x 25 fractions, given over 5 weeks for a total dose of 4300 cGy (4300 rads), then coned-down boost of 172 cGy (rads) fractions x 10 fractions, given over 2 weeks for a dose of 1720 cGy (rads), and a total cumulative dose of 6020 cGy (rads)
One course, followed by:
Chemotherapy
- Carmustine (BiCNU) 80 mg/m2 IV over 30 to 60 minutes once per day on days 1 to 3
8-week cycles, with no more than a maximum total dose of 1500 mg/m2 Carmustine (BiCNU) given
Supportive care:
- Pulmonary function tests (PFTs) checked before start of therapy, and then when cumulative dose of Carmustine (BiCNU) reaches 800 mg/m2 and 1200 mg/m2
References
- Shapiro WR, Green SB, Burger PC, Mahaley MS Jr, Selker RG, VanGilder JC, Robertson JT, Ransohoff J, Mealey J Jr, Strike TA et al. Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001. J Neurosurg. 1989 Jul;71(1):1-9. link to original article contains verified protocol PubMed
RT -> PCV
back to top |
RT -> PCV: Radiation Therapy followed by Procarbazine, CCNU (Lomustine), Vincristine
Regimen #1
Study | Evidence | Comparator |
MRC Brain Tumor Working Party 2001 | Phase III | Radiation therapy |
Radiation therapy starts preferably within 3, but no more than 6, weeks after neurosurgery:
Radiotherapy
- Either:
- 2.25 Gy fractions x 20 fractions, given 5 days per week over 4 weeks, total dose of 45 Gy
- or 2 Gy fractions x 30 fractions, given 5 days per week over 6 weeks, total dose of 60 Gy
Chemotherapy begins 3 to 4 weeks after completion of radiation therapy:
Chemotherapy
- Procarbazine (Matulane) 100 mg/m2 PO once per day on days 1 to 10
- Lomustine (Ceenu) 100 mg/m2 PO once on day 1
- Vincristine (Oncovin) 1.5 mg/m2 (maximum dose of 2 mg) IV fast infusion once on day 1
Supportive medications
- Corticosteroid use was left up to physician discretion. It was recommended to not discontinue steroids until at least 6 weeks after radiation therapy. If it was to be discontinued, it should be tapered down gradually over several weeks, or could be titrated down to the lowest tolerated dose.
6-week cycle for up to 12 cycles
Regimen #2
Study | Evidence | Comparator |
van den Bent et al. 2006 (EORTC 26951) | Phase III | Radiation therapy |
van den Bent et al. 2013 noted that 1p/19q-codeleted tumors received the more benefit from adjuvant PCV as compared to tumors without 1p/19q codeletion.
Radiation therapy starts within 6 weeks after surgery.
Radiotherapy
- Radiation therapy, 1.8 Gy fractions x 25 fractions, given 5 days per week, total dose of 45 Gy to the planning target volume (PTV-1); then a boost of 1.8 Gy fractions x 8 fractions, given 5 days per week, total boost dose of 14.4 Gy to the PTV-2, for a total cumulative dose of 59.4 Gy
Chemotherapy begins within 4 weeks after completion of radiation therapy:
Chemotherapy
- Procarbazine (Matulane) 60 mg/m2 PO once per day on days 8 to 21
- Lomustine (Ceenu) 110 mg/m2 PO once on day 1
- Vincristine (Oncovin) 1.4 mg/m2 (maximum dose of 2 mg) IV once per day on days 8 & 29
Supportive medications
- Antiemetics for Lomustine (Ceenu): "Domperidone (Motilium) or Metoclopramide (Reglan), and if necessary, Ondansetron (Zofran) or a similar agent"
- Corticosteroids kept at lowest possible dose
6-week cycle for 6 cycles
References
- Levin VA, Silver P, Hannigan J, Wara WM, Gutin PH, Davis RL, Wilson CB. Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys. 1990 Feb;18(2):321-4. PubMed
- Medical Research Council Brain Tumor Working Party. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. J Clin Oncol. 2001 Jan 15;19(2):509-18. link to original article contains verified protocol PubMed
- van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Haaxma-Reiche H, Kros JM, van Kouwenhoven MC, Vecht CJ, Allgeier A, Lacombe D, Gorlia T. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol. 2006 Jun 20;24(18):2715-22. link to original article contains verified protocol PubMed
- Update: van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre JY, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Enting RH, French PJ, Dinjens WN, Vecht CJ, Allgeier A, Lacombe D, Gorlia T, Hoang-Xuan K. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol. 2013 Jan 20;31(3):344-50. Epub 2012 Oct 15. link to original article PubMed
Temozolomide (Temodar)
back to top |
Regimen #1
Study | Evidence | Comparator |
Wick et al. 2009 (NOA-04) | Phase III | PCV Radiation therapy |
Chemotherapy
- Temozolomide (Temodar) 200 mg/m2 PO once per day on days 1 to 5
28-day cycle for 8 cycles
Patients with stable disease or better received 4 more cycles of temozolomide. At time of disease progression patients proceeded to receive radiation therapy.
Regimen #2
Study | Evidence |
Mikkelsen et al. 2009 | Non-randomized |
This regimen is meant for patients with 1p/19q loss of heterozygosity (LOH).
Chemotherapy
- Temozolomide (Temodar) as follows:
- Cycles 1 & 2: 150 mg/m2 PO once per day on days 1 to 5, on empty stomach
- Cycle 3 onwards (if no myelosuppression): 200 mg/m2 PO once per day on days 1 to 5, on empty stomach
28-day cycles
Regimen #3
Study | Evidence |
Taliansky-Aronov et al. 2006 | Non-randomized |
Chemotherapy
- Temozolomide (Temodar) 200 mg/m2 PO once per day on days 1 to 5
Supportive medications
- Corticosteroids could be continued at same dose or reduced, but not increased while on study
28-day cycles, given until progression of disease or, in patients with stable disease, up to 24 months
References
- Taliansky-Aronov A, Bokstein F, Lavon I, Siegal T. Temozolomide treatment for newly diagnosed anaplastic oligodendrogliomas: a clinical efficacy trial. J Neurooncol. 2006 Sep;79(2):153-7. Epub 2006 Jul 20. link to original article contains verified protocol PubMed
- Mikkelsen T, Doyle T, Anderson J, Margolis J, Paleologos N, Gutierrez J, Croteau D, Hasselbach L, Avedissian R, Schultz L. Temozolomide single-agent chemotherapy for newly diagnosed anaplastic oligodendroglioma. J Neurooncol. 2009 Mar;92(1):57-63. Epub 2008 Nov 15. link to original article contains verified protocol PubMed content property of HemOnc.org
- Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, Sabel MC, Koeppen S, Ketter R, Meyermann R, Rapp M, Meisner C, Kortmann RD, Pietsch T, Wiestler OD, Ernemann U, Bamberg M, Reifenberger G, von Deimling A, Weller M. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol. 2009 Dec 10;27(35):5874-80. Epub 2009 Nov 9. link to original article contains verified protocol PubMed
Temozolomide -> Temozolomide & RT -> Temozolomide
back to top |
Regimen
Study | Evidence |
Mikkelsen et al. 2009 | Non-randomized |
This regimen is meant for patients without 1p/19q loss of heterozygosity (LOH).
Chemotherapy
- Temozolomide (Temodar) as follows:
- Cycles 1 & 2: 150 mg/m2 PO once per day on days 1 to 5, on empty stomach
- Cycle 3 onwards (if no myelosuppression): 200 mg/m2 PO once per day on days 1 to 5, on empty stomach
28-day cycle for 2 to 4 cycles, followed by:
Chemoradiotherapy
- Temozolomide (Temodar) 75 mg/m2 PO once per day during radiation therapy
- Concurrent radiation therapy with a total dose of 60 Gy
One course, followed by:
Chemotherapy
- Temozolomide (Temodar) 150 to 200 mg/m2 PO once per day on days 1 to 5, on empty stomach
28-day cycles
References
- Mikkelsen T, Doyle T, Anderson J, Margolis J, Paleologos N, Gutierrez J, Croteau D, Hasselbach L, Avedissian R, Schultz L. Temozolomide single-agent chemotherapy for newly diagnosed anaplastic oligodendroglioma. J Neurooncol. 2009 Mar;92(1):57-63. Epub 2008 Nov 15. link to original article contains verified protocol PubMed content property of HemOnc.org
Anaplastic glioma - recurrent disease, salvage therapy
Bevacizumab (Avastin)
back to top |
Regimen
Study | Evidence |
Chamberlain et al. 2008 | Non-randomized |
Chemotherapy
- Bevacizumab (Avastin) 10 mg/kg IV over 30 minutes once on day 1
Supportive medications
- Use of steroids allowed for control of neurologic signs and symptoms
14-day cycles
References
- Chamberlain MC, Johnston S. Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma. J Neurooncol. 2009 Feb;91(3):359-67. Epub 2008 Oct 25. J Neurooncol. 2009 Feb;91(3):359-67. Epub 2008 Oct 25. link to original article contains verified protocol PubMed
- Retrospective: Chamberlain MC, Johnston S. Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma. Cancer. 2009 Apr 15;115(8):1734-43. link to original article PubMed
Bevacizumab & Carboplatin
back to top |
Regimen #1
Study | Evidence |
Thompson et al. 2010 | Retrospective |
Chemotherapy
- Bevacizumab (Avastin) 10 mg/kg IV once on day 1
- Carboplatin (Paraplatin) AUC 5 IV once on day 1
28-day cycles
Regimen #2
Study | Evidence |
Norden et al. 2008 | Retrospective |
Chemotherapy
- Bevacizumab (Avastin) 10 mg/kg IV once every 2 weeks
- Carboplatin (Paraplatin) AUC 5 to 6 IV (reference does not list schedule of carboplatin)
References
- Retrospective: Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, Kesari S, Wen PY. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. 2008 Mar 4;70(10):779-87. link to original article PubMed
- Retrospective: Thompson EM, Dosa E, Kraemer DF, Neuwelt EA. Treatment with bevacizumab plus carboplatin for recurrent malignant glioma. Neurosurgery. 2010 Jul;67(1):87-93. link to original article PubMed
Bevacizumab & Irinotecan
back to top |
Regimen
Study | Evidence |
Vredenburgh et al. 2007 | Phase II |
Note: Vredenburgh et al. 2007 described 6-week cycles in which treatment was every 2 weeks and was otherwise identical, so its entry was consolidated with Taillibert et al. 2009.
Chemotherapy
- Irinotecan (Camptosar) 125 mg/m2 IV over 90 minutes once on day 1, given first
- Patients receiving enzyme-inducing antiepileptic drugs (EIAEDs) are treated with a higher dose: 340 mg/m2 IV over 90 minutes once on day 1, given first
- Bevacizumab (Avastin) 10 mg/kg IV once on day 1, given second
- Infusion times for bevacizumab are 90 minutes for the first dose, then if tolerated, 60 minutes for the second dose, and 30 minutes for the third dose and later
Supportive medications
- "Appropriate antiemetics"
14-day cycles
References
- Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH, Friedman HS. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007 Feb 15;13(4):1253-9. link to original article contains verified protocol PubMed
- Retrospective: Taillibert S, Vincent LA, Granger B, Marie Y, Carpentier C, Guillevin R, Bellanger A, Mokhtari K, Rousseau A, Psimaras D, Dehais C, Sierra del Rio M, Meng Y, Laigle-Donadey F, Hoang-Xuan K, Sanson M, Delattre JY. Bevacizumab and irinotecan for recurrent oligodendroglial tumors. Neurology. 2009 May 5;72(18):1601-6. link to original article PubMed
Cyclophosphamide (Cytoxan)
back to top |
Regimen
Study | Evidence |
Chamberlain et al. 2006 | Phase II |
Chemotherapy
- Cyclophosphamide (Cytoxan) 750 mg/m2 IV over 30 minutes once per day on days 1 & 2
Supportive medications
- Dexamethasone (Decadron) allowed for control of neurologic symptoms
- Ondansetron (Zofran) 0.15 mg/kg IV once prior to cyclophosphamide
- Dexamethasone (Decadron) 4 mg IV once prior to cyclophosphamide
- 1 liter normal saline IV over 2 hours prior to cyclophosphamide
- Prochlorperazine (Compazine) (dose/schedule not specified) prn nausea/vomiting
28-day cycles
References
- Chamberlain MC, Tsao-Wei DD, Groshen S. Salvage chemotherapy with cyclophosphamide for recurrent temozolomide-refractory anaplastic astrocytoma. Cancer. 2006 Jan 1;106(1):172-9. link to original article contains verified protocol PubMed
Etoposide (Vepesid)
back to top |
Regimen
Study | Evidence |
Fulton et al. 1996 | Phase II |
Chemotherapy
- Etoposide (Vepesid) 50 mg PO once per day
Given until progression of disease or unacceptable toxicity
References
- Fulton D, Urtasun R, Forsyth P. Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma. J Neurooncol. 1996 Feb;27(2):149-55. link to original article contains verified protocol PubMed
Irinotecan (Camptosar)
back to top |
Regimen #1
Study | Evidence |
Chamberlain et al. 2008 | Phase II |
Chemotherapy
- Irinotecan (Camptosar) 350 mg/m2 IV over 120 minutes once on day 1
- Patients receiving enzyme-inducing antiepileptic drugs (EIAEDs) are treated with a higher dose: 600 mg/m2 IV over 120 minutes once on day 1
Supportive medications
- Dexamethasone (Decadron) allowed for control of neurologic symptoms
- 500 mL normal saline IV over 1 hour prior to irinotecan
- Intravenous Ondansetron (Zofran), Granisetron (Kytril), or Dolasetron (Anzemet) as antiemetic prior to irinotecan
- Dexamethasone (Decadron) 20 mg IV once prior to irinotecan
- Atropine (Atropen) 0.5 mg IV once prior to irinotecan
- Prochlorperazine (Compazine) (dose/schedule not specified) prn nausea/vomiting
- Loperamide (Imodium) (dose/schedule not specified) prn diarrhea
21-day cycles
Regimen #2
Study | Evidence |
Friedman et al. 1999 | Phase II |
Chemotherapy
- Irinotecan (Camptosar) 125 mg/m2 IV once per day on days 1, 8, 15, 22
- If tolerated, dose could be increased to 150 mg/m2 IV once per day on days 1, 8, 15, 22
Supportive medications
- Steroids at lowest dose necessary
- Avoid laxatives and magnesium-containing antacids due to potential for diarrhea
42-day (6-week) cycles, given until progression of disease or unacceptable toxicity
References
- Friedman HS, Petros WP, Friedman AH, Schaaf LJ, Kerby T, Lawyer J, Parry M, Houghton PJ, Lovell S, Rasheed K, Cloughsey T, Stewart ES, Colvin OM, Provenzale JM, McLendon RE, Bigner DD, Cokgor I, Haglund M, Rich J, Ashley D, Malczyn J, Elfring GL, Miller LL. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol. 1999 May;17(5):1516-25. link to original article contains verified protocol PubMed
- Phase I: Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent oligodendrogliomas. J Neurooncol. 2002 Sep;59(2):157-63. link to original article PubMed
- Chamberlain MC, Wei-Tsao DD, Blumenthal DT, Glantz MJ. Salvage chemotherapy with CPT-11 for recurrent temozolomide-refractory anaplastic astrocytoma. Cancer. 2008 May 1;112(9):2038-45. link to original article contains verified protocol PubMed
Lomustine (Ceenu)
back to top |
- Note: The NCCN, Central Nervous System Cancers version 1.2013 lists this regimen (Wick et al. 2010) with Lomustine (Ceenu) salvage therapy in glioblastoma multiforme as an option for treatment of anaplastic gliomas. This study only included patients who had histologically confirmed WHO grade 4 glioblastoma. The NCCN also listed the following phase II trial as a reference for use of Carmustine (BiCNU)/Lomustine (Ceenu) in recurrent malignant glioma, but the nitrosourea used was fotemustine (FTM): R. Soffietti, R. Rudà, E. Trevisan, E. Picco, D. Guarneri, M. Caroli, M. Fabrini, V. Scotti. Phase II study of bevacizumab and nitrosourea in patients with recurrent malignant glioma: A multicenter Italian study. CNS Tumors 2012 J Clin Oncol 27:15s, 2009 (suppl; abstr 2012). 2009 ASCO Annual Meeting abstract 2012. link to abstract
PCV
back to top |
PCV: Procarbazine, CCNU (Lomustine), Vincristine
Regimen #1
Study | Evidence | Comparator |
Wick et al. 2009 (NOA-04) | Phase III | Temozolomide |
All patients had progressed after previously receiving radiation therapy, salvage temozolomide, or salvage radiation therapy.
Chemotherapy
- Procarbazine (Matulane) 60 mg/m2 PO once per day on days 8 to 21
- Lomustine (Ceenu) 110 mg/m2 PO once on day 1
- Vincristine (Oncovin) 2 mg IV once per day on days 8 & 29
8-week cycles until progression
At progression, patients who had not previously received temozolomide proceeded to receive salvage temozolomide.
Regimen #2
Study | Evidence |
Levin et al. 1980 | Non-randomized |
Chemotherapy
- Procarbazine (Matulane) 60 mg/m2 PO once per day on days 8 to 21
- Lomustine (Ceenu) 110 mg/m2 PO once on day 1
- Vincristine (Oncovin) 1.4 mg/m2 (maximum dose of 2 mg) IV once per day on days 8 & 29
6-week cycles, given until progression of disease or unacceptable toxicity
Regimen #3, higher doses
Study | Evidence |
Cairncross et al. 1994 | Phase II |
Chemotherapy
- Procarbazine (Matulane) 75 mg/m2 PO once per day on days 8 to 21
- Lomustine (Ceenu) 130 mg/m2 PO once on day 1
- Vincristine (Oncovin) 1.4 mg/m2 (dose not capped) IV once per day on days 8 & 29
6-week cycles, given until progression of disease or unacceptable toxicity
References
- Levin VA, Edwards MS, Wright DC, Seager ML, Schimberg TP, Townsend JJ, Wilson CB. Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors. Cancer Treat Rep. 1980 Feb-Mar;64(2-3):237-44. contains protocol PubMed
- Cairncross G, Macdonald D, Ludwin S, Lee D, Cascino T, Buckner J, Fulton D, Dropcho E, Stewart D, Schold C Jr et al. Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1994 Oct;12(10):2013-21. link to original article contains verified protocol PubMed
- Kappelle AC, Postma TJ, Taphoorn MJ, Groeneveld GJ, van den Bent MJ, van Groeningen CJ, Zonnenberg BA, Sneeuw KC, Heimans JJ. PCV chemotherapy for recurrent glioblastoma multiforme. Neurology. 2001 Jan 9;56(1):118-20. link to original article PubMed
- Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, Sabel MC, Koeppen S, Ketter R, Meyermann R, Rapp M, Meisner C, Kortmann RD, Pietsch T, Wiestler OD, Ernemann U, Bamberg M, Reifenberger G, von Deimling A, Weller M. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol. 2009 Dec 10;27(35):5874-80. Epub 2009 Nov 9. link to original article contains verified protocol PubMed
Radiation therapy
back to top |
Regimen
Study | Evidence | Comparator |
Wick et al. 2009 (NOA-04) | Phase III | PCV Temozolomide |
Patients had previously received PCV versus temozolomide prior to progression.
Radiotherapy
- Radiation therapy with 1.8 to 2 Gy fractions given over 6 weeks for a total dose of 60 Gy
Patients who progressed then received PCV if they had previously received temozolomide, or temozolomide if they had previously received PCV.
References
- Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, Sabel MC, Koeppen S, Ketter R, Meyermann R, Rapp M, Meisner C, Kortmann RD, Pietsch T, Wiestler OD, Ernemann U, Bamberg M, Reifenberger G, von Deimling A, Weller M. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol. 2009 Dec 10;27(35):5874-80. Epub 2009 Nov 9. link to original article contains verified protocol PubMed
Temozolomide (Temodar)
back to top |
Regimen #1
Study | Evidence | Comparator |
Wick et al. 2009 (NOA-04) | Phase III | PCV |
All patients had progressed after previously receiving radiation therapy, salvage PCV, or salvage radiation therapy.
Chemotherapy
- Temozolomide (Temodar) 200 mg/m2 PO once per day on days 1 to 5
28-day cycles until progression
At progression, patients who had not previously received PCV proceeded to receive salvage PCV.
Regimen #2, continuous therapy
Study | Evidence |
Perry et al. 2008 (RESCUE) | Phase II |
Patients who undergo conventional temozolomide therapy, have surgery and radiation therapy, and then relapse receive:
Chemotherapy
- Temozolomide (Temodar) 150 to 200 mg/m2 PO once per day on days 1 to 5
28-day cycles
Patients with progressive disease are changed to:
- Temozolomide (Temodar) 50 mg/m2 PO once per day, taken continuously without treatment break
Given until progression of disease or unacceptable toxicity
Regimen #3, traditional dosing
Study | Evidence |
Nicholson et al. 2007 | Non-randomized |
Chemotherapy
- Temozolomide (Temodar) 200 mg/m2 PO once per day on days 1 to 5
- Patients who previously received craniospinal irradiation (CSI) instead received 180 mg/m2 PO once per day on days 1 to 5
28-day cycle for up to 11 cycles
Regimen #4
Study | Evidence |
Yung et al. 1999 | Phase II |
Chemotherapy
- Temozolomide (Temodar) as follows:
- Patients who had never previously received chemotherapy: 200 mg/m2 PO once per day on days 1 to 5
- Patients who previously received chemotherapy started with 150 mg/m2 PO once per day on days 1 to 5, which could be increased as tolerated to 200 mg/m2 PO once per day on days 1 to 5
Supportive medications
- Prophylactic antiemetics as needed
- Lowest dose of corticosteroids necessary to maintain neurologic stability
28-day cycle for up to 2 years
References
- Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, Albright R, Olson J, Chang SM, O'Neill AM, Friedman AH, Bruner J, Yue N, Dugan M, Zaknoen S, Levin VA. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol. 1999 Sep;17(9):2762-71. link to original article contains verified protocol PubMed
- Nicholson HS, Kretschmar CS, Krailo M, Bernstein M, Kadota R, Fort D, Friedman H, Harris MB, Tedeschi-Blok N, Mazewski C, Sato J, Reaman GH. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer. 2007 Oct 1;110(7):1542-50. link to original article contains verified protocol PubMed
- Perry JR, Rizek P, Cashman R, Morrison M, Morrison T. Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach. Cancer. 2008 Oct 15;113(8):2152-7. link to original article contains verified protocol PubMed
- Update: Perry JR, Bélanger K, Mason WP, Fulton D, Kavan P, Easaw J, Shields C, Kirby S, Macdonald DR, Eisenstat DD, Thiessen B, Forsyth P, Pouliot JF. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol. 2010 Apr 20;28(12):2051-7. Epub 2010 Mar 22. link to original article contains verified protocol PubMed
- Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, Sabel MC, Koeppen S, Ketter R, Meyermann R, Rapp M, Meisner C, Kortmann RD, Pietsch T, Wiestler OD, Ernemann U, Bamberg M, Reifenberger G, von Deimling A, Weller M. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol. 2009 Dec 10;27(35):5874-80. Epub 2009 Nov 9. link to original article contains verified protocol PubMed
Glioblastoma multiforme chemoradiation & adjuvant therapy
Radiation
back to top |
Regimen
Study | Evidence | Comparator |
Stupp et al. 2005 | Phase III | Radiation & Temozolomide -> Temozolomide |
Adjuvant radiation alone; used as a comparator arm in the referenced trials.
References
- Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005 Mar 10;352(10):987-96. link to original article contains verified protocol PubMed
Radiation & Carmustine (BiCNU)
back to top |
Regimen
Study | Evidence | Comparator |
Shapiro et al. 1989 (BTCG 8001) | Phase III | Carmustine/Procarbazine & RT Carmustine & Hydrea/Procarbazine & VM-26 & RT |
Radiotherapy
- Radiation therapy starting within 3 weeks after surgical resection, with one of the following:
- Whole brain: 172 cGy (rads) fractions x 35 fractions, given over 7 weeks for a total dose of 6020 cGy (6020 rads/~1700 rets)
- Whole brain & cone down: 172 cGy (rads) fractions x 25 fractions, given over 5 weeks for a total dose of 4300 cGy (4300 rads), then coned-down boost of 172 cGy (rads) fractions x 10 fractions, given over 2 weeks for a dose of 1720 cGy (rads), and a total cumulative dose of 6020 cGy (rads)
One course, followed by:
Chemotherapy
- Carmustine (BiCNU) 80 mg/m2 IV over 30 to 60 minutes once per day on days 1 to 3
8-week cycles, with no more than a maximum total dose of 1500 mg/m2 Carmustine (BiCNU) given
Supportive care:
- Pulmonary function tests (PFTs) checked before start of therapy, and then when cumulative dose of Carmustine (BiCNU) reaches 800 mg/m2 and 1200 mg/m2
References
- Shapiro WR, Green SB, Burger PC, Mahaley MS Jr, Selker RG, VanGilder JC, Robertson JT, Ransohoff J, Mealey J Jr, Strike TA et al. Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001. J Neurosurg. 1989 Jul;71(1):1-9. link to original article contains verified protocol PubMed
Radiation & Temozolomide -> Temozolomide
back to top |
Regimen
Study | Evidence | Comparator |
Stupp et al. 2005 | Phase III | Radiation |
Gilbert et al. 2014 | Phase III | Bevacizumab, Temozolomide, RT |
Chinot et al. 2014 | Phase III | Bevacizumab, Temozolomide, RT |
Chemoradiotherapy
- Temozolomide (Temodar) 75 mg/m2 PO once per day, used starting the first day of radiation therapy until the last day of radiation therapy, and no longer than 49 days
- Concurrent radiation therapy, 2 Gy fractions x 30 fractions given 5 days per week, for a total dose of 60 Gy
Supportive medications
- PCP prophylaxis with one of the following:
- Trimethoprim/Sulfamethoxazole (Bactrim)
- Pentamidine (Nebupent) 300 mg nebulized inhaled
- Metoclopramide (Reglan) or 5-HT3 antagonist recommended before the initial doses of radiation therapy & temozolomide
One course
4 weeks after completion of radiation therapy, patients received additional therapy:
Chemotherapy
- Temozolomide (Temodar) as follows:
- Cycle 1: 150 mg/m2 PO once per day on days 1 to 5
- If tolerated, in cycles 2 to 6: 200 mg/m2 PO once per day on days 1 to 5
Supportive medications
- Metoclopramide (Reglan) or 5-HT3 antagonist required
28-day cycle for 6 cycles
References
- Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005 Mar 10;352(10):987-96. link to original article contains verified protocol PubMed
- Subgroup analysis: Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005 Mar 10;352(10):997-1003. link to original article PubMed
- Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ Jr, Mehta MP. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014 Feb 20;370(8):699-708. link to original article PubMed
- Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L, Cloughesy T. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014 Feb 20;370(8):709-22. link to original article PubMed
Glioblastoma multiforme - recurrent disease, salvage therapy
Bevacizumab (Avastin)
back to top |
Regimen #1
Study | Evidence | Comparator |
Friedman et al. 2009 | Randomized Phase II | Bevacizumab & Irinotecan |
Chemotherapy
- Bevacizumab (Avastin) 10 mg/kg IV once per day on days 1, 15, 29
6-week cycle for up to 104 weeks, until progression of disease, or unacceptable toxicity
Regimen #2
Study | Evidence |
Kreisl et al. 2008 | Phase II |
Chemotherapy
- Bevacizumab (Avastin) 10 mg/kg IV once per day on days 1 & 15
4-week cycles, given until progression of disease, or unacceptable toxicity; upon progression, patients received Irinotecan (Camptosar) & Bevacizumab (Avastin)
References
- Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS, Fine HA. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009 Feb 10;27(5):740-5. Epub 2008 Dec 29. link to original article contains verified protocol PubMed
- Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009 Oct 1;27(28):4733-40. Epub 2009 Aug 31. link to original article contains verified protocol PubMed
Bevacizumab & Carboplatin
back to top |
Regimen #1
Study | Evidence |
Thompson et al. 2010 | Retrospective |
Chemotherapy
- Bevacizumab (Avastin) 10 mg/kg IV once on day 1
- Carboplatin (Paraplatin) AUC 5 IV once on day 1
28-day cycles
Regimen #2
Study | Evidence |
Norden et al. 2008 | Retrospective |
Chemotherapy
- Bevacizumab (Avastin) 10 mg/kg IV once every 2 weeks
- Carboplatin (Paraplatin) AUC 5 to 6 IV (reference does not list schedule of carboplatin)
References
- Retrospective: Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, Kesari S, Wen PY. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. 2008 Mar 4;70(10):779-87. link to original article PubMed
- Retrospective: Thompson EM, Dosa E, Kraemer DF, Neuwelt EA. Treatment with bevacizumab plus carboplatin for recurrent malignant glioma. Neurosurgery. 2010 Jul;67(1):87-93. link to original article PubMed
Bevacizumab & Irinotecan
back to top |
Regimen #1, every 2 week schedule
Study | Evidence | Comparator |
Chen et al. 2007 | Pilot, >20 pts | |
Vredenburgh et al. 2007 | Phase II | |
Norden et al. 2008 | Phase II | |
Friedman et al. 2009 | Randomized Phase II | Bevacizumab |
Note: Friedman et al. 2009 described 6-week cycles in which treatment was every 2 weeks, given up to 104 weeks, and was otherwise identical, so its entry was consolidated with the other ones here.
Chemotherapy
- Irinotecan (Camptosar) 125 mg/m2 IV over 90 minutes once on day 1, given first
- Patients receiving enzyme-inducing antiepileptic drugs (EIAEDs) are treated with a higher dose: 340 mg/m2 (Vredenburgh et al. 2007 & Norden et al. 2008) or 350 mg/m2 (Chen et al. 2007) IV over 90 minutes once on day 1, given first
- Bevacizumab (Avastin) 10 mg/kg IV once on day 1, given second, 90 minutes after the start of irinotecan
- Infusion times for bevacizumab are 90 minutes for the first dose, then if tolerated, 60 minutes for the second dose, and 30 minutes for the third dose and later
Supportive medications
- Steroids were generally maintained at the same dose
14-day cycles, given until progression of disease or unacceptable toxicity
Regimen #2
Study | Evidence |
Vredenburgh et al. 2007 | Phase II, <20 pts |
Chemotherapy
- Irinotecan (Camptosar) 125 mg/m2 IV over 90 minutes once per day on days 1, 8, 22, 29, given first
- Patients receiving enzyme-inducing antiepileptic drugs (EIAEDs) are treated with a higher dose: 350 mg/m2 IV over 90 minutes once per day on days 1, 8, 22, 29, given first
- Bevacizumab (Avastin) 15 mg/kg IV once per day on days 1 & 22, given second, 90 minutes after the start of irinotecan
- Infusion times for bevacizumab are 90 minutes for the first dose, then if tolerated, 60 minutes for the second dose, and 30 minutes for the third dose and later
Supportive medications
- Steroids were generally maintained at the same dose
42-day (6-week) cycles, given until progression of disease or unacceptable toxicity
References
- Chen W, Delaloye S, Silverman DH, Geist C, Czernin J, Sayre J, Satyamurthy N, Pope W, Lai A, Phelps ME, Cloughesy T. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol. 2007 Oct 20;25(30):4714-21. link to original article contains verified protocol PubMed
- Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007 Oct 20;25(30):4722-9. link to original article contains verified protocol PubMed
- Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, Kesari S, Wen PY. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. 2008 Mar 4;70(10):779-87. link to original article contains verified protocol PubMed
- Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009 Oct 1;27(28):4733-40. Epub 2009 Aug 31. link to original article contains verified protocol PubMed
Carmustine (BiCNU)
back to top |
Regimen
Study | Evidence |
Brandes et al. 2004 | Phase II |
Chemotherapy
- Carmustine (BiCNU) 80 mg/m2 IV once per day on days 1 to 3
Supportive medications
- Antiemesis prophylaxis with Ondansetron (Zofran)
- Steroids at lowest dose necessary
8-week cycle for up to 6 cycles
References
- Brandes AA, Tosoni A, Amistà P, Nicolardi L, Grosso D, Berti F, Ermani M. How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial. Neurology. 2004 Oct 12;63(7):1281-4. link to original article contains verified protocol PubMed
Cyclophosphamide (Cytoxan)
back to top |
Regimen
Study | Evidence |
Chamberlain & Tsao-Wei, 2004 | Phase II |
Chemotherapy
- Cyclophosphamide (Cytoxan) 750 mg/m2 IV over 30 minutes once per day on days 1 & 2
Supportive medications
- Dexamethasone (Decadron) allowed for control of neurologic symptoms
- Ondansetron (Zofran) 0.15 mg/kg IV once prior to cyclophosphamide
- Dexamethasone (Decadron) 4 mg IV once prior to cyclophosphamide
- 1 liter normal saline IV over 2 hours prior to cyclophosphamide
- Prochlorperazine (Compazine) (dose/schedule not specified) prn nausea/vomiting
28-day cycles
References
- Chamberlain MC, Tsao-Wei DD. Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme. Cancer. 2004 Mar 15;100(6):1213-20. link to original article contains verified protocol PubMed
Hydroxyurea & Imatinib
back to top |
Regimen
Study | Evidence |
Dresemann et al. 2005 | Non-randomized |
Chemotherapy
- Imatinib (Gleevec) 400 mg PO once per day
- Hydroxyurea (Hydrea) 500 mg PO BID
Given until progression of disease
References
- Dresemann G. Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series. Ann Oncol. 2005 Oct;16(10):1702-8. Epub 2005 Jul 20. link to original article contains verified protocol PubMed
Irinotecan (Camptosar)
back to top |
Regimen
Study | Evidence |
Friedman et al. 1999 | Phase II |
Chemotherapy
- Irinotecan (Camptosar) 125 mg/m2 IV once per day on days 1, 8, 15, 22
- If tolerated, dose could be increased to 150 mg/m2 IV once per day on days 1, 8, 15, 22
Supportive medications
- Steroids at lowest dose necessary
- Avoid laxatives and magnesium-containing antacids due to potential for diarrhea
42-day (6-week) cycles, given until progression of disease or unacceptable toxicity
References
- Friedman HS, Petros WP, Friedman AH, Schaaf LJ, Kerby T, Lawyer J, Parry M, Houghton PJ, Lovell S, Rasheed K, Cloughsey T, Stewart ES, Colvin OM, Provenzale JM, McLendon RE, Bigner DD, Cokgor I, Haglund M, Rich J, Ashley D, Malczyn J, Elfring GL, Miller LL. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol. 1999 May;17(5):1516-25. link to original article contains verified protocol PubMed
Lomustine (Ceenu)
back to top |
Regimen
Study | Evidence | Comparator |
Wick et al. 2010 | Phase III | Enzastaurin |
Chemotherapy
- Lomustine (Ceenu) 100 to 130 mg/m2 PO once on day 1
Supportive medications
- Enzyme-inducing antiepileptic drugs (EIAEDs) needed to be discontinued 14 days before enrolling in the trial
6-week cycles, given until progression of disease or unacceptable toxicity
References
- Wick W, Puduvalli VK, Chamberlain MC, van den Bent MJ, Carpentier AF, Cher LM, Mason W, Weller M, Hong S, Musib L, Liepa AM, Thornton DE, Fine HA. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol. 2010 Mar 1;28(7):1168-74. Epub 2010 Feb 1. link to original article contains verified protocol PubMed
PCV
back to top |
PCV: Procarbazine, CCNU (Lomustine), Vincristine
Regimen #1
Study | Evidence |
Levin et al. 1980 | Non-randomized |
Chemotherapy
- Procarbazine (Matulane) 60 mg/m2 PO once per day on days 8 to 21
- Lomustine (Ceenu) 110 mg/m2 PO once on day 1
- Vincristine (Oncovin) 1.4 mg/m2 (maximum dose of 2 mg) IV once per day on days 8 & 29
6-week cycles, given until progression of disease or unacceptable toxicity
Regimen #2, higher doses
Study | Evidence |
Cairncross et al. 1994 | Phase II |
Chemotherapy
- Procarbazine (Matulane) 75 mg/m2 PO once per day on days 8 to 21
- Lomustine (Ceenu) 130 mg/m2 PO once on day 1
- Vincristine (Oncovin) 1.4 mg/m2 (dose not capped) IV once per day on days 8 & 29
6-week cycles, given until progression of disease or unacceptable toxicity
References
- Levin VA, Edwards MS, Wright DC, Seager ML, Schimberg TP, Townsend JJ, Wilson CB. Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors. Cancer Treat Rep. 1980 Feb-Mar;64(2-3):237-44. contains protocol PubMed
- Cairncross G, Macdonald D, Ludwin S, Lee D, Cascino T, Buckner J, Fulton D, Dropcho E, Stewart D, Schold C Jr et al. Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1994 Oct;12(10):2013-21. link to original article contains verified protocol PubMed
Procarbazine (Matulane)
back to top |
Regimen
Study | Evidence |
Yung et al. 2000 | Phase II |
Chemotherapy
- Procarbazine (Matulane) as follows:
- Patients who had never previously received chemotherapy: 150 mg/m2 PO once per day on days 1 to 28
- Patients who previously received chemotherapy started with 125 mg/m2 PO once per day on days 1 to 28
Supportive medications
- Steroids at lowest dose necessary
8-week cycle for up to 2 years, progression of disease, or unacceptable toxicity
References
- Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Vick NA, Rampling R, Friedman H, Phillips P, Bruner J, Yue N, Osoba D, Zaknoen S, Levin VA. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 2000 Sep;83(5):588-93. link to original article contains verified protocol PubMed
Temozolomide (Temodar)
back to top |
Regimen #1, continuous therapy
Study | Evidence |
Perry et al. 2008 (RESCUE) | Phase II |
Chemotherapy
Patients who have first recurrence after surgery and conventional external beam radiation:
- Temozolomide (Temodar) 150 to 200 mg/m2 PO once per day on days 1 to 5
28-day cycles
Patients with progressive disease are changed to:
- Temozolomide (Temodar) 50 mg/m2 PO once per day, taken continuously without treatment break
Given until progression of disease or unacceptable toxicity
Patients who had recurrent/progressive disease after surgery and concurrent radiation and temozolomide are treated with:
- Temozolomide (Temodar) 50 mg/m2 PO once per day, taken continuously without treatment break
Given until progression of disease or unacceptable toxicity
Regimen #2, traditional dosing
Study | Evidence |
Nicholson et al. 2007 | Non-randomized |
Chemotherapy
- Temozolomide (Temodar) 200 mg/m2 PO once per day on days 1 to 5
- Patients who previously received craniospinal irradiation (CSI) instead received 180 mg/m2 PO once per day on days 1 to 5
28-day cycle for up to 11 cycles
Regimen #3
Study | Evidence |
Yung et al. 2000 | Phase II |
Chemotherapy
- Temozolomide (Temodar) as follows:
- Patients who had never previously received chemotherapy: 200 mg/m2 PO once per day on days 1 to 5
- Patients who previously received chemotherapy started with 150 mg/m2 PO once per day on days 1 to 5
28-day cycle for up to 2 years, until progression of disease, or unacceptable toxicity
References
- Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Vick NA, Rampling R, Friedman H, Phillips P, Bruner J, Yue N, Osoba D, Zaknoen S, Levin VA. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 2000 Sep;83(5):588-93. link to original article contains verified protocol PubMed
- Nicholson HS, Kretschmar CS, Krailo M, Bernstein M, Kadota R, Fort D, Friedman H, Harris MB, Tedeschi-Blok N, Mazewski C, Sato J, Reaman GH. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer. 2007 Oct 1;110(7):1542-50. link to original article contains verified protocol PubMed
- Perry JR, Rizek P, Cashman R, Morrison M, Morrison T. Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach. Cancer. 2008 Oct 15;113(8):2152-7. link to original article contains verified protocol PubMed
- Update: Perry JR, Bélanger K, Mason WP, Fulton D, Kavan P, Easaw J, Shields C, Kirby S, Macdonald DR, Eisenstat DD, Thiessen B, Forsyth P, Pouliot JF. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol. 2010 Apr 20;28(12):2051-7. Epub 2010 Mar 22. link to original article contains verified protocol PubMed
Supratentorial astrocytoma or oligodendroglioma chemoradiation & adjuvant therapy
Temozolomide (Temodar)
back to top |
Regimen
Note: The patients in the reference were treated for glioblastoma, but the NCCN, Central Nervous System Cancers version 1.2013 lists this as an acceptable regimen for supratentorial astrocytoma or oligodendroglioma. No primary reference could be found for this regimen in this disease.
Chemoradiotherapy
- Concurrent radiation therapy, 2 Gy fractions x 30 fractions given 5 days per week, for a total dose of 60 Gy
- Temozolomide (Temodar) 75 mg/m2 PO once per day, used starting the first day of radiation therapy until the last day of radiation therapy, and no longer than 49 days
4 weeks after completion of radiation therapy, patients received additional adjuvant therapy:
- Temozolomide (Temodar) 150 mg/m2 PO once per day on days 1 to 5 of cycle 1; if tolerated, in cycles 2 and on, the dose is increased to Temozolomide (Temodar) 200 mg/m2 PO once per day on days 1 to 5
Supportive medications
- PCP prophylaxis during radiation therapy & temozolomide with one of the following:
- Trimethoprim/Sulfamethoxazole (Bactrim)
- Pentamidine (Nebupent) 300 mg nebulized inhaled
- Metoclopramide (Reglan) or 5-HT3 antagonist required during the adjuvant temozolomide-only period; their use was also recommended before the initial doses of radiation therapy & temozolomide
28-day cycle for 6 cycles
References
- Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005 Mar 10;352(10):987-96. link to original article contains verified protocol PubMed
Supratentorial astrocytoma or oligodendroglioma - recurrent or progressive, low-grade disease
Carboplatin (Paraplatin)
back to top |
Regimen
Study | Evidence |
Moghrabi et al. 1998 | Phase II |
Chemotherapy
- Carboplatin (Paraplatin) 560 mg/m2 IV over 1 hour once on day 1
- Mixed in D5 1/2 NS
Supportive medications
- Hydration for 1 hour before chemotherapy, and for 1 hour after chemotherapy; total volume including carboplatin is 900 mL/m2
28-day cycle for up to 12 cycles beyond the maximum response, given until progression of disease, or unacceptable toxicity
References
- Moghrabi A, Friedman HS, Ashley DM, Bottom KS, Kerby T, Stewart E, Bruggers C, Provenzale JM, Champagne M, Hershon L, Watral M, Ryan J, Rasheed K, Lovell S, Korones D, Fuchs H, George T, McLendon RE, Friedman AH, Buckley E, Longee DC. Phase II study of carboplatin (CBDCA) in progressive low-grade gliomas. Neurosurg Focus. 1998 Apr 15;4(4):e3. link to original article contains verified protocol PubMed
Carboplatin & Teniposide
back to top |
Regimen
Study | Evidence |
Brandes et al. 2003 | Phase II |
Chemotherapy
- Carboplatin (Paraplatin) 350 mg/m2 IV once on day 1
- Teniposide (Vumon) 50 mg/m2 IV once per day on days 1 to 3
Supportive medications
- Prophylactic 5-HT3 antagonists routinely used
- Lowest dose of corticosteroids necessary to maintain neurologic stability
- Antiepileptic medications for all patients
28-day cycle for up to 10 cycles
References
- Brandes AA, Basso U, Vastola F, Tosoni A, Pasetto LM, Jirillo A, Lonardi S, Paris MK, Koussis H, Monfardini S, Ermani M. Carboplatin and teniposide as third-line chemotherapy in patients with recurrent oligodendroglioma or oligoastrocytoma: a phase II study. Ann Oncol. 2003 Dec;14(12):1727-31. link to original article contains verified protocol PubMed
Cisplatin & Etoposide
back to top |
Regimen
Study | Evidence |
Massimino et al. 2010 | Non-randomized |
Note: In children <1 year old or <10 kg, "doses were adjusted to their weight"--reference does not say exactly how doses are adjusted.
Chemotherapy
- Cisplatin (Platinol) 25 mg/m2 IV over 2 hours once per day on days 1 to 3, given first
- Etoposide (Vepesid) 100 mg/m2 IV over 30 minutes once per day on days 1 to 3, given second
Supportive medications
- Hydration for 2 hours before chemotherapy, and for 2 hours after chemotherapy
28-day cycle for 4 cycles, then 35-day cycle for 3 cycles, then 42-day cycle for 3 cycles
References
- Massimino M, Spreafico F, Riva D, Biassoni V, Poggi G, Solero C, Gandola L, Genitori L, Modena P, Simonetti F, Potepan P, Casanova M, Meazza C, Clerici CA, Catania S, Sardi I, Giangaspero F. A lower-dose, lower-toxicity cisplatin-etoposide regimen for childhood progressive low-grade glioma. J Neurooncol. 2010 Oct;100(1):65-71. Epub 2010 Feb 12. link to original article contains verified protocol PubMed
PCV
back to top |
PCV: Procarbazine, CCNU (Lomustine), Vincristine
Regimen
Study | Evidence |
Brandes et al. 2004 | Phase II |
Chemotherapy
- Procarbazine (Matulane) 60 mg/m2 PO once per day on days 8 to 21
- Lomustine (Ceenu) 110 mg/m2 PO once on day 1
- Vincristine (Oncovin) 1.4 mg/m2 (maximum dose of 2 mg) IV once per day on days 8 & 29
Supportive medications
- Routine use of prophylactic 5-HT3 antagonists
- Steroids given at the lowest dose required by patient's neurologic status
6-week cycle for up to 6 cycles
References
- Brandes AA, Tosoni A, Vastola F, Pasetto LM, Coria B, Danieli D, Iuzzolino P, Gardiman M, Talacchi A, Ermani M. Efficacy and feasibility of standard procarbazine, lomustine, and vincristine chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. Cancer. 2004 Nov 1;101(9):2079-85. link to original article contains verified protocol PubMed
- Triebels VH, Taphoorn MJ, Brandes AA, Menten J, Frenay M, Tosoni A, Kros JM, Stege EB, Enting RH, Allgeier A, van Heuvel I, van den Bent MJ. Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas. Neurology. 2004 Sep 14;63(5):904-6. link to original article PubMed
Temozolomide (Temodar)
back to top |
Regimen #1, low dose
Study | Evidence |
Pouratian et al. 2006 | Retrospective |
Chemotherapy
- Temozolomide (Temodar) 75 mg/m2 PO once per day on days 1 to 21
Supportive medications
- PCP prophylaxis with Trimethoprim/Sulfamethoxazole (Bactrim)
- Antiemetics and stool softeners used as needed
28-day cycle for 12 to 15 cycles
Regimen #2, low dose, longer cycles
Study | Evidence |
Kesari et al. 2009 | Phase II |
Chemotherapy
- Temozolomide (Temodar) 75 mg/m2 PO once per day on days 1 to 49
Supportive medications
- PCP prophylaxis with Trimethoprim/Sulfamethoxazole (Bactrim)
77-day cycle for up to 6 cycles, progression of disease, or unacceptable toxicity
Regimen #3, traditional initial dosing, then continuous therapy
Study | Evidence |
Perry et al. 2008 (RESCUE) | Phase II |
At first recurrence/progression:
Chemotherapy
- Temozolomide (Temodar) 150 to 200 mg/m2 PO once per day on days 1 to 5
28-day cycles
Patients with progressive disease are changed to:
- Temozolomide (Temodar) 50 mg/m2 PO once per day, taken continuously without treatment break
Given until progression of disease or unacceptable toxicity
Regimen #4, traditional dosing
Study | Evidence |
Chinot et al. 2001 | Phase II |
Nicholson et al. 2007 | Non-randomized |
Chemotherapy
- Temozolomide (Temodar) 200 mg/m2 PO once per day on days 1 to 5
- In Nicholson et al. 2007, patients who previously received craniospinal irradiation (CSI) instead received 180 mg/m2 PO once per day on days 1 to 5
28-day cycle for up to 24 months (in Chinot et al. 2001) or 11 cycles (in Nicholson et al. 2007)
References
- Chinot OL, Honore S, Dufour H, Barrie M, Figarella-Branger D, Muracciole X, Braguer D, Martin PM, Grisoli F. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J Clin Oncol. 2001 May 1;19(9):2449-55. link to original article contains verified protocol PubMed
- Pouratian N, Gasco J, Sherman JH, Shaffrey ME, Schiff D. Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas. J Neurooncol. 2007 May;82(3):281-8. Epub 2006 Nov 3. link to original article contains verified protocol PubMed
- Nicholson HS, Kretschmar CS, Krailo M, Bernstein M, Kadota R, Fort D, Friedman H, Harris MB, Tedeschi-Blok N, Mazewski C, Sato J, Reaman GH. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer. 2007 Oct 1;110(7):1542-50. link to original article contains verified protocol PubMed
- Perry JR, Rizek P, Cashman R, Morrison M, Morrison T. Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach. Cancer. 2008 Oct 15;113(8):2152-7. link to original article contains verified protocol PubMed
- Update: Perry JR, Bélanger K, Mason WP, Fulton D, Kavan P, Easaw J, Shields C, Kirby S, Macdonald DR, Eisenstat DD, Thiessen B, Forsyth P, Pouliot JF. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol. 2010 Apr 20;28(12):2051-7. Epub 2010 Mar 22. link to original article contains verified protocol PubMed
- Kesari S, Schiff D, Drappatz J, LaFrankie D, Doherty L, Macklin EA, Muzikansky A, Santagata S, Ligon KL, Norden AD, Ciampa A, Bradshaw J, Levy B, Radakovic G, Ramakrishna N, Black PM, Wen PY. Phase II study of protracted daily temozolomide for low-grade gliomas in adults. Clin Cancer Res. 2009 Jan 1;15(1):330-7. link to original article contains verified protocol PubMed